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Abstract 
The aims of this project were to introduce the VITEK 2 Compact and to 
implement European Committee Antimicrobial Susceptibility Testing 
guidelines in a small microbiology department. The VITEK 2 Compact is 
an automated analyser for the identification and antimicrobial susceptibility 
testing of bacteria and has been associated with decreased sample turn-
around-times, cost savings and improved detection of multi-drug resistant 
organisms. There are 10 different guidelines for the clinical interpretation 
of antimicrobial susceptibility data. A national decision was made in 2010 
to harmonise susceptibility data reporting in Ireland, by adopting European 
Committee Antimicrobial Susceptibility Testing guidelines. This will enable 
the comparison of data between institutions at the patient, national and 
internationally level. The HSE Change Model was used to guide the 
change process. A vision for change, aligned with the organisations strong 
commitment to quality was created along with the key stakeholders. The 
vision was communicated along with the drivers for change. A plan was 
developed and implemented which included validation of the new 
processes and a training program. Mini-successes during the initial stages 
of the project were celebrated to ensure mainstreaming. Donabedian’s 
structure, process, outcome model was used for evaluation. Results 
demonstrated cost savings of €2.90-€10.28 per isolate and reduced turn-
around-times of 1-20 hours, depending on organism complexity. Higher 
scores for external quality assurance samples were achieved in a direct 
comparison with historical procedures, demonstrating both trainee 
proficiency and process accuracy. Consumable costs and turn-around 
times were standardised irrespective of pathogen complexity and 
resistance. The turn-around-times for healthcare associated infections has 
been decreased by 20 hours, which has the potential to have a positive 
impact on infection control in the organisation. The implementation of the 
VITEK 2 Compact and European Committee Antimicrobial Susceptibility 
Testing guidelines will also facilitate the application of national guidelines 
for the control of multi-drug resistant organisms in the department. 
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1. Introduction 
1.1 Organisational Context: 
‘Quality’ and ‘Innovation’ are two of seven core values espoused by my 
non-profit organisation, a 150 bedded acute private hospital providing 
both adult and paediatric services. This organisational change project 
sought to improve the quality of the service offered by the microbiology 
department, through the introduction of new technology in the 
department (innovation). The microbiology department offers clinical 
services for the routine culture and identification of bacteria, as well as 
providing antimicrobial susceptibility testing on pathogenic organisms. 
 
During the past number of years, staff numbers have decreased within 
the hospital. All the while, the activity level has increased and with that 
there has been a corresponding increase in the demand for laboratory 
tests. Funding is not available to increase staff numbers. However in 
2014, funding was approved to introduce automation into the 
microbiology department. The VITEK 2 was selected as the instrument 
of choice to meet the increasing needs of the laboratory. 
  
The VITEK 2 system allows for rapid organism identification and 
antimicrobial susceptibility testing which improve clinical outcomes and 
reduce costs (Eigner et al.,  2005). Identification of some bacteria using 
current methods can take up to 48 hours for a result. Using the VITEK 
this time can be dramatically decreased, with some identifications 
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available after 3 hours and all after 24 hours (Ligozzi et al., 2002) in 
comparison to traditional methods which can take up to 48 hours. This 
is important for tailoring antibiotic therapy to meet the individual 
patient’s needs.  
1.2 Rationale: 
When selecting an organisational change project, many different 
options were discussed with my manager. The department had applied 
for capital funding in 2012 but this had been deferred, resulting in little 
capital investment in the department. However in 2014, funding was 
approved to implement automation in the microbiology department. The 
VITEK 2 was selected as the instrument of choice for the identification 
and antimicrobial susceptibility testing (AST) of bacteria and to reduce 
service costs. 
 
Pathogenic bacteria isolated from patient cultures require both 
identification and AST. Historically identification and AST of bacteria 
was performed as two separate laboratory processes. The methodology 
for both is very different and laborious, requiring a minimum of 24 hours 
incubation. Introduction of automation streamlined two separate 
laboratory processes. 
 
The automation of AST enabled the laboratory to more readily 
implement European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) guidelines. AST is used to determine the clinical success or 
13 
 
failure of antimicrobial therapy. Several different guidelines exist for 
AST. There is a significant need to harmonize guidelines, not only to 
compare resistance data nationally and internationally, but for the 
continuity of patient’s results. For example if a patient is undergoing 
treatment at two hospitals and have the same pathogen isolated in two 
microbiology laboratories, identical AST data may be interpreted 
differently, altering the treatment of the patient. The Irish Society of 
Clinical Microbiologists (ISCM) decided that Irish microbiology 
laboratories would adopt EUCAST guidelines (ISCM, personal 
communication, March, 2010). 
 
As well as introduction of EUCAST guidelines, automation of AST yields 
more specific and accurate results. Traditionally disc diffusion methods 
report isolates as sensitive, intermediate or resistant. There is no 
information regarding developing resistance. Through the use of 
automation, developing resistance can be tracked more readily as 
minimum inhibitory concentrations (MIC’s) are reported for each 
antibiotic. MIC’s are gold standard method for performing AST and MIC 
data enables the detection of emerging multidrug resistance organisms 
(MDRO). 
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1.3 Aims and Objectives: 
 Aims:  
1. To introduce the VITEK 2 system into the Microbiology 
Laboratory for the identification and antimicrobial susceptibility 
testing of bacteria and to concurrently implement European 
Committee on Antimicrobial Susceptibility Testing Guidelines for 
reporting antimicrobial susceptibility data by April 2015. 
Objectives: 
1. Perform installation, operational and performance qualifications 
according to manufactures instructions on the VITEK 2 Compact 
instrument by 27/3/2015. 
2. Validate European Committee on Antimicrobial Susceptibility 
Testing disc diffusion methodology by 27/3/2015 
3. Train all Microbiology Medical Scientist to use the VITEK 2 
Compact and European Committee on Antimicrobial 
Susceptibility Testing Guidelines. Staff will score 100% in post 
training competency tests and will be fully compliant with the new 
procedures by 24/4/2015. 
4. Obtain >95% accuracy in cumulative external quality assurance 
scores for January-March 2015. 
5. Standardise consumable costs for identification and antibiotic 
susceptibility testing of bacteria by 10/4/2015. 
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6. Demonstrate a reduction in turn-around-times for processing 
identification and antibiotic susceptibility of bacteria by 
10/4/2015. 
1.4 Role of the Student: 
The student is a Medical Scientist in the Microbiology Department and 
at the beginning of this project was a new member of staff in the 
organisation, therefore had little influence. Furthermore does not have 
formal authority over any stakeholders involved in this change initiative. 
However the change agent had extensive experience with both the 
VITEK 2 and also with the implementation of EUCAST guidelines in a 
previous role. This enabled the author to lead this change project 
successfully, as time could be focussed on communicating the rationale 
for change and building trusting relationships with new colleagues, 
rather than dwelling on the technical aspects of the project.  This was 
important particularly at the beginning of the project as the author was 
unfamiliar with the culture and politics of the organisation.  
 
Prior experience also allowed the change agent to augment the vision 
for change with personal experiences and this was a further source of 
motivation for change. Knowledge and skills from past experience also 
enabled the change agents to deliver the majority of the training 
program.  
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The role of the change agent is a supporter of the people (empathetic) 
in an organisation and a questioner the status quo who must negotiate 
the power and politics in an organisation to achieve change (McAuliffe 
and Vaerenbergh, 2006). Furthermore the change agent must keep 
lines of communication open, analyse the situation, reflect, share credit 
with others and be aspirational within time limits (McAuliffe & 
Vaerenbergh, 2006). To lead change successfully the agent must also 
be willing to experiment with the selected change model to ensure it fits 
the organisation (Van de Ven and Sun, 2011). The change agent was 
conscious of all of these factors through-out the change project and 
reflection was also a key practice (McAuliffe and Vaerenbergh, 2006; 
Van de Ven and Sun, 2011).  
1.5 Summary: 
The thesis will begin with a literature review of topics relevant to this 
project, focussing particularly on the implications of laboratory 
automation and the impact on changing AST guidelines. Chapter three 
will critically discuss the rationale for selecting the Health Service 
Executive (HSE) Change Model (HSE, 2008) to guide this project. 
Furthermore a detailed description how each stage of the model was 
used to guide the change will follow. Chapter four outlines the extensive 
evaluation of the introduction of automation and EUCAST guidelines on 
the laboratory. Finally chapter five will discuss the project impact, 
successes of this change and opportunity for improvements. 
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2.0 Literature Review 
2.1 Introduction 
There were two primary aims of this literature review. First, to determine 
the evidence for automation in microbiology, with a particular focus on 
smaller microbiology departments. Second, to determine the evidence 
for implementing EUCAST guidelines in the laboratory. In addition to 
the primary aims, the challenges and benefits of automation and the 
effect of the changing from Clinical and Laboratory Standards Institute 
(CLSI) guidelines to EUCAST guidelines will also be explored. Finally a 
number of other themes which emerged in the literature review, such as 
the value of the advanced expert system (AES), detection of antibiotic 
resistance and adding quality to the microbiology report will also be 
discussed.  
 
2.2 Search Strategy: 
The Literature Review carried out as part of this project drew involved 
primary searches using PubMed and Web of Science. Searches of 
these databases were performed using the key words; laboratory 
automation, microbiology automation, antimicrobial susceptibility 
testing, VITEK and EUCAST. The search was limited to journal articles 
in the English language and from 1990 to date (February 2015). All 
articles relating to mycology and molecular microbiology were excluded.  
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In addition to the search criteria outlined above, EUCAST guidelines 
and relevant published journal articles were accessed from 
www.eucast.org. The Health Information and Quality Authority (HIQA) 
and Health Protection and Surveillance Centre (HPSC) websites were 
also used to access relevant information. Finally a search of Irish 
literature was conducted on Lenus (the Irish Repository) using the 
following search terms ‘EUCAST’ (13 articles) and ‘VITEK’ (16 articles) 
to locate any relevant Irish Literature.  
2.3 Evidence for Change; Laboratory Automation 
2.3.1 Drivers for Change 
Historically automation has been embraced by clinical laboratories other 
than microbiology (Bourbeau and Ledeboer, 2013). Microbiology was 
by-passed until recent years, largely due to complexity of sample types 
received into the laboratory (for example; urines, faeces, sputa, blood 
cultures, wound swabs and tissue samples), the different culture media 
required, the long incubation time and the large diversity of 
microorganisms cultured. This is in contrast to the one sample type 
(blood) received into biochemistry and haematology  (Bourbeau and 
Ledeboer, 2013).  
 
In recent years automation of bacterial identification and antimicrobial 
susceptibility testing (AST) has been implemented in large laboratories 
with high-through-put. Smaller laboratories generally have little 
automation, other than the continuous monitoring of blood cultures. In 
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the past, automation in smaller laboratories was considered an under-
utilisation of resources (Bourbeau and Ledeboer, 2013), however  new 
drivers for automation in smaller laboratories have emerged in recent 
years. 
 
The first driver for laboratory automation in smaller laboratories is the 
requirement for accreditation of microbiology services in Ireland (HIQA, 
2009). Key aspects of laboratory accreditation are the precise pre-
analytical, analytical and post-analytical processing with the 
standardisation of procedures yielding accurate, reproducible and 
reliable results, all in accordance with relevant guidelines and 
standards, to ensure the quality of the service provided. The 
accreditation process exerts pressure on limited laboratory resources, 
therefore resource planning and management must be central to any 
accreditation plan (Yenice, 2009). Automation enables standardisation 
of laboratory processes and reduction in time taken to issue laboratory 
results (Camporese, 2004), yielding time for staff to focus on competing 
demands (Garcia-Irure et al., 2002).  
 
A second driver for automation is the increasing requirement for greater 
efficiency and a reduction in turn-around-times (TATs) for laboratory 
reports. Due to the nature of microbiology, and the requirement of 
overnight incubation of primary patient samples before the identification 
and susceptibility testing of bacteria, TATs of microbiology samples 
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traditionally range from 24-114 hours (Camporese, 2004). The TATs 
vary greatly, depending on the type of sample, the requirement for AST 
and the complexity of the organism cultured.  
 
2.3.2 VITEK 2(bioMérieux) and the Impact of Change 
The VITEK is an automated instrument for the identification and AST of 
bacteria (Ligozzi et al., 2002; Ling et al., 2001; Mazzariol et al., 2008).  
The instrument was first developed in the 1970’s and has evolved into 
the VITEK 2 today. It automatically performs all of the steps required for 
identification and AST of bacteria, after a primary inoculum has been 
prepared and standardized (Ligozzi et al., 2002).  
 
The VITEK 2 compares well with the main competing instrument on the 
market, the Phoenix (BD Diagnostic Systems, Sparks, MD, USA). 
Eigner et al., (2005) demonstrated that the Phoenix and VITEK 2 
obtained the same results for staphylococci and enterococci in 
comparison to reference methods. For 140 Enterobacteriaceae strains 
evaluated, 135 (96%) were correctly identified by Phoenix and 137 
(98%) by VITEK 2. When comparing AST data overall MIC category 
agreement for AST was 97% for both instruments in comparison to 
reference methods. In terms of workflow Eigner et al., (2005) concluded 
that the VITEK 2 required less manipulation time and results were 
available faster in comparison to the Phoenix instrument. Comparable 
AST performances for both instruments have also been reported by 
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Woodford et al., (2010), Sader et al., (2006) and Treviño et al., (2009) 
for the detection of multi-drug resistant bacteria. This is not surprising 
as both instruments are based on broth micro-dilution methods for AST 
and miniature biochemical and chromogenic tests for identification 
(Carroll et al., 2006; Ligozzi et al., 2002). 
 
Mulatero et al., (2011) reported that with an average of 22 specimens 
processed per day (small laboratory), use of the VITEK 2 saved 80 
minutes per day of hands-on time as compared with routine manual 
methods. For larger laboratories the saved hands-on-time has been 
reported as high as 11.6 hours (Stoiljković et al., 2011). Mulatero et al., 
(2011) also reported a reduction of consumables. There was a cost 
saving of £0.70 for the identification of bacteria per sample in 
comparison to manual methods. Finally they reported a reduction in 
TAT by 16 hours (24 hours to 8 hours) for 80% of samples.  This study 
echoes findings by others such as Vargas et al., (2005) who reported 
that TAT also decreased from 24 hours to 8 hours for AST results. This 
had a potential clinical impact on 40% of the patients in the 
retrospective evaluation, where the organism was resistant to the 
antibiotic therapy prescribed and appropriate therapy could have been 
prescribed sooner.  
 
The most comprehensive study examining the impact of rapid AST on 
patient care was performed by Barenfanger et al., (1999). They report a 
22 
 
reduction in AST TAT from 20 hours to 15 hours in a comparative study 
performed over a seven month period in a large 500 bed hospital (rapid 
AST method versus conventional method). The reduction in TAT for 
reporting AST results was associated with significant cost savings, as 
the patients were prescribed the appropriate antibiotic therapy sooner, 
thereby reducing their hospital stay. The cost savings to the 
organisation were based on fixed direct, variable direct and fixed 
indirect costs and where shown to be on average $2,395 per patient. 
The hospital stay was also decreased by two days but there was no 
effect on mortality reported. There is no comment regarding the case-
mix in the organisation or the complexity of the bacterial isolates 
included in the study.  
 
2.3.3 Laboratory Experiences with Automation  
As automation is relatively new to microbiology, it is important to 
determine the long-term impact of automation on the laboratory and if 
there are any learning points that can be applied to microbiology. The 
impact the VITEK 2 has on laboratory reporting errors is not mentioned 
in any of the papers included in this review. One experience in clinical 
chemistry found that in the early days following the implementation of 
automation, staff morale was low, the TAT’s did not decrease as 
expected and there was an increase in laboratory errors (Lam and 
Jacob, 2012). Furthermore Valenstein et al., (2010) reported that using 
automation creates the potential for large scale systemic errors 
affecting many patient samples until they are discovered. The use of 
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internal quality control and external quality assurance (EQA) can be 
used to detect such errors, but it is important for laboratories to be 
aware of their potential. 
 
Other studies found that automation has reduced laboratory errors 
associated with the analytical phase of sample testing (McCay et al., 
2009; Plebani et al., 2014) This enables the laboratory to then focus on 
error reduction in the pre-analytical and post-analytical stages of 
laboratory testing (McCay et al., 2009; Rin, 2010) which is very 
important for patient safety.  
 
2.4 Evidence for Change; EUCAST Guidelines 
2.4.1 Drivers for Change 
Antibiotic susceptibility results are used for treating individual patients 
with the most appropriate antibiotic, form the basis for selecting empiric 
therapy and influence local, national and international antibiotic 
prescribing data. The raw data generated by AST in the laboratory must 
be translated into susceptible, intermediate or resistant categories. This 
is achieved using AST guidelines (breakpoints). Breakpoints are 
specific for each drug-bacteria combination and are defined by intrinsic 
resistance, pharmacokinetic and clinical data (Jorgensen, 2004).  
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In 2004 there were seven different guidelines in place across 28 states 
(six of these were in Europe) (Cornaglia et al., 2004). In 2003 the need 
for European harmonization of AST guidelines for bacteria was 
highlighted and it was reported that it is not uncommon for the same 
organism to be regarded as susceptible in some countries but resistant 
in others (Kahlmeter et al., 2003).  This data can be extrapolated 
nationally. In Ireland some laboratories report AST data using CLSI 
guidelines, while others use EUCAST guideline. Problems arise, when 
patients are transferred from one institution to another and the AST 
data is reported differently.  This problem has a ripple effect, as it 
results in difficulties with comparing antimicrobial surveillance results 
both nationally and internationally, as well as in communicating the 
efficacy of specific drugs between healthcare professionals and 
pharmaceutical companies (Kahlmeter et al., 2003). 
 
The CLSI describes itself as ‘an international, interdisciplinary, non-
profit, standards-developing and educational organization that promotes 
the development and use of voluntary consensus standards and 
guidelines within the health care community. The organization further 
states that it is recognized worldwide for the application of its unique 
consensus process in the development of standards and guidelines for 
patient testing and related health care issues’ (Jenkins and Jerris, 
2011). However in recent years there has been increasing input from 
the Food and Drug Administration (FDA) (USA) and pharmaceutical 
companies, in the development of guidelines. Jorgensen (2004) 
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highlights the benefit to pharmaceutical companies associated with 
favourable breakpoints. Questions have emerged over the transparency 
of the process (Jenkins and Jerris, 2011). Also CLSI documents are not 
open source and must be purchased annually.  
 
Stakeholders from all European countries were invited to participate in 
developing EUCAST standard operating procedures (SOPs) and each 
country had a representative on the committee (including Ireland) 
(Kahlmeter and Brown, 2004). The development of EUCAST guidelines 
was strongly evidence based. There was great emphasis placed on 
compatibility with the ISO (International Standardisation Organization) 
standards (Bengtsson et al., 2014) . For transparency and to ensure 
greater confidence in the methodologies used to gather epidemiological 
data EUCAST also published a series of technical notes on specific 
antibiotics (Kahlmeter et al., 2006). EUCAST guidelines are open-
source and are available to download with yearly updates at 
www.eucast.org. 
 
By 2013 it was estimated that 70% of clinical microbiology departments 
in Europe had made the transition to EUCAST guidelines (Kahlmeter, 
2014). In a survey of European Laboratories in 2013 it was shown that 
between 10-50% of laboratories in Ireland had adopted EUCAST 
guidelines (Brown et al., 2015). See Figure 1 below. The survey also 
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highlighted that 10-50% of laboratories in Australia have also adopted 
the guidelines. 
  
Figure 1 Results from EUCAST Survey 2013 (Brown et al., 2015) 
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2.4.2 Impact of Change 
Before implementing EUCAST guidelines and methodologies, a 
validation of the system must be performed (Matuschek et al., 2014). 
There is a strict protocol which must be adhered. This is important to 
ensure standardisation of the results and the correct use of the 
guideline. Implementation guidance documents are published on the 
EUCAST website www.eucast.org as well as the guidelines.  
 
Currently, laboratories in Europe are encouraged to adopt EUCAST 
guidelines to facilitate comparability of AST results. Many of the 
laboratories adopting these guidelines will be changing from CLSI 
guidelines. However, EUCAST fail to acknowledge the significant 
transition from one guideline to another. A gap analysis of the two 
guidelines or comparison of the two guidelines would be beneficial. 
Furthermore, there are only a limited number of studies on this and the 
majority relate to Enterobacteriaceae.  
 
Hombach et al.,  (2011) argue that EUCAST guideline will result in a 
greater number of organisms being reported as resistant and that this 
will have an effect on the antimicrobial prescribing policies of healthcare 
facilities. This study examined gram negative organisms only and was a 
comparison study applying both breakpoints. It resulted in some 
reclassifications of susceptibility. However, the data should not be mis-
interpreted as the authors made the assumption that this would change 
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in prescribing policies and this in turn would drive antibiotic resistance. 
Van der Bij et al., (2012) examined the impact changing guidelines had 
on antibiotic resistance data for one gram negative organism, 
Escherichia coli in Holland, post implementation of EUCAST 
breakpoints. They also anticipated that this would result in a greater 
number of organisms being reported as resistance. However this study 
demonstrated that there was little effect on the overall susceptibility 
data reported for E. coli when moving from CLSI to EUCAST guidelines.  
 
The Study for Monitoring Antimicrobial Resistance Trends (SMART)  is 
a longitudinal surveillance study that tracks susceptibility and trends of 
pathogens causing intra-abdominal infections worldwide. They reported 
that all multi-drug resistant isolates of E. coli, Klebsiella 
pneumoniae and Klebsiella oxytoca  collected from 2008–2009 would 
have antibiotic susceptibility data reported similarly, when using either 
CLSI or EUCAST guidelines (Hawser et al., 2010).  
 
Hombach et al., (2011) reviewed AST data from a wide range of gram 
negative bacteria while Hawser et al., (2010) and van der Bij et al., 
(2012) focussed on members of the Enterobacteriaceae family only (E. 
coli, K. pneumoniae and K. oxytoca). Acinetobacter Pseudomonas and 
Stenotrophomonas species are intrinsically more resistant to antibiotics 
than members of the Enterobacteriaeceae family (Leclercq et al., 2011) 
and this may account for the difference in the study findings.  It is 
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evident from these reports that more studies are required to investigate 
the true impact changing guidelines has on reporting resistance and the 
association if any, with antibiotic prescribing habits.   
 
The mentioned studies relate to gram negative bacteria, there is little 
data on gram positive organisms such as Staphylococci, Enterococci or 
Streptococcal species. One study examining 13,716 gram positive 
bacterial strains and interpreting tetracycline MICs using CLSI and 
EUCAST guidelines, reported that fewer infections would be treatable 
with tetracycline when EUCAST guidelines are used (Jones et al., 
2013). This study suggested that harmonisation of EUCAST and CLSI 
guidelines aligned with pharmacokinetic data would benefit the users of 
both guidelines. However this study does not address the impact on 
other antibiotics or on prescribing policies.  
 
2.5 VITEK 2 and EUCAST Guidelines: 
2.5.1 Antibiotic Resistance 
EUCAST published Expert Rules (Leclercq et al., 2011) which aim to 
assist microbiologists to infer AST data from one agent to another, to 
supress AST results from reporting which may be inappropriate and  to 
edit AST results based on inferred resistance mechanisms. EUCAST 
recommend that laboratories incorporate these rules into their 
laboratory information system (LIS) or into their automated instrument.  
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The VITEK 2 has advanced expert software (AES) which analyses the 
AST data using a knowledge base of 2000 phenotypes and 20,000 MIC 
distributions (Barry et al., 2003) and incorporates EUCAST expert rules. 
This enables analysis of susceptibility patterns rather than individual 
AST results, therefore underlying resistance mechanisms may be 
detected. This is very important for smaller laboratories, where there is 
low incidence and therefore little experience with emerging 
MDRO(Barry et al., 2003). Furthermore the bioART software on the 
VITEK 2 enables users to configure to highlight the possibility new 
emerging resistance (HSE RCPI clinical advisory group on HCAI., 
2013). This resulted in the detection of emerging antibiotic resistance 
mechanisms such as carbapenem resistant Enterobacteriaceae (CRE) 
that were previously undetected in Ireland (O’Brien et al., 2011). 
 
2.5.2 Laboratory Reports 
The benefit of automated bacterial identification and AST has also been 
demonstrated to improve the quality of service offered by the laboratory. 
Garcia-Irure et al., (2002) noted that the reduced hands-on-time 
associated with the VITEK enable microbiology staff to allocate more 
time to guiding clinician on appropriate antibiotic therapy and improving 
the reporting process. Clinicians felt this was a significant quality 
improvement by the microbiology department. Cunney and Smyth 
(2000) argue that only appropriate patient centred comments should be 
added to laboratory reports and warn against adding too many 
automated interpretive comments. EUCAST guidelines contain many 
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interpretive clinical comments regarding antibiotic dosing. It is important 
that laboratories consider the quality of laboratory reports and the 
relevance of any comments added to ensure that the most relevant 
information is communicated to the users.  
2.6 Future Opportunities for Automation in Microbiology: 
When considering a capital investment it is essential to ensure that the 
technology being purchased will not become obsolete in the near future. 
Automation in microbiology emerged much later than automation in 
other pathology disciplines. However in recent year numerous 
processes have been automated in the laboratory such as sample 
inoculation, incubation, plate streaking, gram staining and the 
aforementioned identification and AST (Buchan and Ledeboer, 2014). 
One of the most significant technologies to arrive in microbiology in 
recent years is matrix-assisted laser desorption/ionisation-time of flight 
(MALDI-tof). This allows for the rapid identification of microorganisms; 
within 15-30 seconds. This is very significant in microbiology as 
identifications can still take 4-20 hours using the VITEK 2. The major 
reduction in turn-around-time has been shown to improve clinical 
outcomes for the patient and also has a positive impact on antibiotic 
stewardship programs (Buchan and Ledeboer, 2014). One large 
laboratory in the U.S. reported annual savings of $102,424 a reduction 
of 56.9% (including reagent, labour, and maintenance costs) (Tan et al., 
2012). However this cannot be translated into the smaller laboratory as 
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the maintenance contract and significant capital cost of the instrument 
would be prohibitory. 
2.7 Laboratory Training 
Implementation of the VITEK 2 Compact and EUCAST guidelines 
requires staff training. Detailed training records and evidence of 
competency must be retained by the department according to 
ISO:15189 accreditation standards (ISO:15189, 2012). Competency 
assessment can be used to demonstrate employees have the ability to 
perform accurate laboratory testing in a timely manner (Sharp and 
Elder, 2004). A limitation of competency assessment is that it 
demonstrates areas of competency but incompetency may remain 
detected (Sharp and Elder, 2004).  
 
EQA schemes can be used both for competency assessment post 
training and for the validation of new processes (Libeer, 2001). These 
schemes can also be used as performance indicators (PI) (Royal 
College of Pathologists, 2011). Implementation of EUCAST guidelines 
will enable benchmarking of microbiology departments using EQA data 
(Kahlmeter et al., 2003). However there are limitations of solely using 
EQA results as for proficiency/competency assessment post training 
and as a PI for the organisation. Many factors may influence the results 
for example; participant bias, EQA samples may be treated differently to 
patient samples and internal quality control issues (Shahangian, 1998). 
33 
 
Therefore EQA results alone should not be used for validation of new 
processes, trainee competency assessment and as a laboratory PI.  
 
2.8 Conclusion 
Read et al.,  (2011) highlight that automation and accreditation in 
microbiology favours the larger laboratories. The great challenge for 
smaller laboratories is to offer a high quality, patient focussed, 
accredited laboratory services within financial constraints. The reduction 
in hospital stays for patients has placed another pressure on 
microbiology services to provide more rapid test results. The VITEK 2 is 
an option which has been proven to reduce turn-around times and 
improve the quality and reproducibility of microbiology results.  
 
There are numerous studies demonstrating the positive attributes of 
automation as previously discussed. However there is very little data 
published on the impact more rapid turn-around-time has on patient 
outcomes. Bourbeau and Ledeboer  (2013) argue that a series of 
studies examining the benefits to different patient groups needs to be 
performed to identify the real impact of automation.  
 
Implementing EUCAST guidelines ensures that Irish laboratories are 
working on-par with their European counter-parts. This facilitates 
reporting into European antimicrobial resistance surveillance systems 
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such as EARRSnet (O’Brien and Stelling, 2011), enabling Ireland to 
monitor antibiotic resistance data in comparison to other European 
countries. Furthermore the use of automated AST systems enables 
smaller laboratories to detect and monitor the emergence of resistance, 
particularly through the use of Expert Rules as recommended by 
EUCAST (Leclercq et al., 2011). Despite the fact that newer technology 
exists (MALDI-tof) for the identification of bacteria, the VITEK 2 still 
remains the best option for smaller laboratories in terms of cost and 
through-put.  
 
A published gap analysis on the differences between CLSI and 
EUCAST would be beneficial to laboratories contemplating a change of 
guideline. More studies on the impact of changing guidelines would 
enable laboratories and clinicians to change guidelines, with greater 
confidence on the affect that this will have on the day-to-day running of 
the laboratory, prescribing habits and the resistance data. This may 
become significant if hospitals become required to publish their 
antimicrobial resistance data.  
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2.8 Literature Review: Implications for this project: 
There are a number of implications for this project arising from the 
literature review. A gap analysis on the differences between CLSI and 
EUCAST will be required. The VITEK 2 may result in the detection of 
MDRO (previously undetected in the organisation) and the 
implementing EUCAST guidelines may alter the AST data generated by 
the department.  Only EUCAST interpretative comments which are 
pertinent to the care of an individual patient should appear on the 
laboratory report. It will be important to communicate these findings to 
stakeholders.  
 
The AST comparison criteria outlined by Eigner et al., (2005) can be 
used to evaluate the performance qualification of the VITEK 2 
instrument. EQA results can be used for competency assessment and 
for validating the new processes; however results should not be used in 
isolation.  
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3.0 Methodology 
3.1 Introduction: 
This chapter will begin with a brief critical discussion on change 
management theories (planned, emergent, contingency and 
organisational development (OD)). This will be followed by the rationale 
for selecting the HSE Change Model for this project. Finally the 
application of the change model into practise will then be described. 
3.2 Critical Review of Approaches to Change: 
Lewin (1951) proposed the three-step model for change. This model 
suggests that for change to be successful and sustained, three steps 
should be involved;  
1. unfreezing the present state,  
2. moving to the new state  
3. refreezing at the new desired state.  
This three-step model forms the building blocks for planned models. 
Kotter (1995) also proposed a planned model, comprising of eight 
individual stages. Each stage is completed in a step-wise manner, 
where progression to the next stage is only when the previous has been 
completed.  
 
It has been argued that planned change models are not applicable to 
rapid, radical changes in a dynamic and chaotic environment. For this 
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reason emergent models were developed. Emergent models are based 
on the premise that there is a need for flexibility and time for learning 
during change. Change is unpredictable and therefore should not be a 
linear stepwise process (Burnes, 1996). Emergent models adopted a 
‘bottom up’ approach, where there is an assumption that it is impossible 
for senior managers to identify, plan and implement the necessary 
organisational changes (Burnes, 1996).  Pettigrew and Whipp 
(1993)proposed an emergent model which focussed on organisations 
becoming learning systems and relied on five inter-related activities.  
 
Burnes (2004) argues that the emergent models are based on the 
assumption that all organisations operate in a turbulent, unpredictable 
environment and that is not always the case. Contingency models 
acknowledge that organisations operate under different circumstances 
and there is more than one approach to change. One example of this 
model was introduced by Kanter (1992), who suggested that there can 
be two different approaches adopted by an organisation. ‘Bold strokes’ 
which are major change initiatives which are imposed from the top-
down and ‘long strokes which are a series of small-scale, local 
changes, implemented from the bottom-up. Burnes (1996) argues that 
when using the contingency theory organisations still have no choice, 
they must still identify key contingencies and adopt the prescribed 
approach.  
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Organisational development (OD) is another approach to planned 
organisational change. The following are a number of characteristics 
which distinguish OD from a more general change management 
approach interdisciplinary approach, values driven, focuses on both 
processes and content, committed to transfer of knowledge and skill to 
creating a learning organisation, is a collaborative top-down, bottom-up 
approach that recognises the importance of building the commitment 
and leadership of top-level decision makers and involving all 
stakeholder in the change process (McAuliffe and Van Vaerenbergh 
2006).  
 
OD models are based on two important characteristics. First there is a 
framework of recognisable phases that transform from the current to the 
more desired future state.  Second there is a collection of activities and 
techniques which help the organisation move through the phases 
(Senior and Swailes, 2006). Action research forms the underlying 
philosophy for OD.  
 
As outlined above there are many different approaches to change and 
there is not one approach that fits all change projects. Burnes (1996) 
noted that it is essential to select a model which best suits the 
organisation and the circumstances. The HSE Change Model (HSE, 
2008) was developed to aid change in the Irish healthcare system and 
is based on theories of OD and project management. It recognises that 
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change occurs in a dynamic, complex environment with many 
stakeholders, therefore cannot be predicted or occur in a stable linear 
way and needs to be an adaptive process. The model was developed in 
recognition of the positive aspects of other change models including 
Kotter (1995) and incorporates the essential stage of evaluation and 
learning. It endeavours to promote a consistent approach to change 
across the healthcare system. Finally it is a cyclical model, which 
enables the user to move freely between stages, including returning to 
previous stages as required, see Figure 2 below.  
 
Figure 2. HSE Change Model (HSE, 2008) 
  
40 
 
3.3 Rationale for OD Model Selected 
On review of change models, it became apparent that different aspects 
of each of the theories/models could be applied to this project. The 
planned models were appealing as they outlined clear steps to achieve 
change. However they assume that change occurs in a stable 
environment and is from the top-down. They also fail to address the 
planning and evaluation stages of the change.  
 
This change project is occurring in a dynamic setting, from the bottom-
up, where the change agent has little power and influence over other 
stakeholders, therefore the emergent models might be more applicable. 
The emergent approaches also promote an open learning system which 
is important in this project. The HSE model also includes all of these 
factors. Guidance is available to the user, both in the user guide but 
also on-line learning tools on the HSE Change Hub. There is a large 
focus on stakeholder involvement which is vital for the success of this 
project.  
 
Van de Ven and Sun (2011) state that more positive learning outcomes 
occur when the change agent reflects during change and is open to 
new ideas in applying their chosen change model to their specific 
organisation. As the HSE model is flexible, it facilitates the change 
agent to progress in a state of trial and error to find the best way to 
achieve organisational change (Van de Ven and Sun, 2011).  
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The HSE change model was selected as it is a model that the change 
agent is familiar with from a previous role. The model has a strong 
evidence base and has been developed to fit the Irish Healthcare 
System. The change agent does not work in the HSE, but in a non-profit 
private healthcare provider, who has strong ties with the HSE in terms 
of education and training of medics, nurses, pharmacists and other 
allied healthcare professional. Therefore many staff members have 
previously worked in the HSE and are familiar with the change model.  
3.4 HSE Change Model 
3.4.1Initiation; Preparing to lead the change 
Before commencing employment in the organisation in December 2014, 
the change agent met with the Laboratory Manager (LM) and Senior 
Medical Scientist (SMS) to discuss the change project. The SMS was 
eager to implement new national guidelines for the control of multidrug 
resistant organisms (MDRO). The change agent was a member of the 
committee who developed the guidelines, therefore had a keen 
personal interest in the successful national implementation of the 
guidelines.  
 
The change agent submitted a project proposal, however on reflection, 
noted that this project was too large for the laboratory until a number of 
other changes were made. The lack of automation and the requirement 
to implement EUCAST guidelines were cited as the main obstacles to 
the ambitious implementation of the new guidelines. The change agent 
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met with the LM who acknowledged the growing need for automation 
but despite this funding for capital projects was not available. 
Coincidently in the days that followed, a representative from the 
manufacturer of the VITEK 2 Compact approached the department 
regarding the acquisition of an instrument through reagent rental, the 
only funding required would be for the interface and maintenance. This 
proposal was approved by hospital management and this change 
project evolved to become the introduction of an automated analyser for 
the identification and AST of bacteria and the implementation of 
EUCAST guidelines.  
 
To access the drivers for change and degree of urgency required, a 
SWOT analysis and force field analysis were performed, see Appendix 
1 and 2. This enabled leverage points and the opportunities for change 
to be discovered. SWOT analysis (Ansoff, 1965) facilitated the 
identification of strengths, weaknesses, opportunities and threats 
relating to the proposed change.  
 
Lewin’s force field analysis was used to conceptualise the drivers and 
resisters to the change from the current situation (manual methods for 
identification and susceptibility testing of bacteria and CLSI guidelines) 
to the future state (automated identification and susceptibility testing of 
bacteria and use of EUCAST guidelines) (Baulcomb, 2003) . These 
results were combined with those from the SWOT analysis to form the 
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vision and drivers for change as well as to document the sources of 
potential resistance. This formed the foundation of the initiation phase.  
 
Literature suggests that resources should be focussed on reducing the 
restraining forces, rather than trying to increase the drivers (McAuliffe & 
Van Vaerenbergh 2006). Therefore the change agent was mindful of 
addressing the following factors when developing the implementation 
plan; lack of skills/knowledge, increase in workload during the infancy of 
the project and disruption to the routine workload.  
 
A stakeholder analysis was performed to identify the key stakeholders 
involved in the change process, with a view to engaging each group. 
This task was the first step undertaken in stakeholder engagement a 
mix of identifying, assessing, prioritizing, communicating and managing 
(Boesso and Kumar, 2009). This analysis was repeated throughout the 
project and can be found in Appendix 3.  
 
An initial assessment of the impact of the change was performed. This 
was a key step to develop the vision for change. It involved redesigning 
the current processes to incorporate the changes.  A risk assessment of 
the new processes was also performed Appendix 4. This was important 
to enable suitable risk reduction controls to be introduced into the 
design of the new processes. The preliminary analysis was performed 
44 
 
by the change agent and this was then discussed with the QM, SMS 
and CM to ensure that they agreed with the initial analysis. Estimated 
time-lines for the project were also discussed and were represented in a 
Gantt Chart (see Appendix 5). 
 
3.4.2 Planning 
The change management tools SWOT analysis, force field analysis, 
stakeholder analysis and risk assessment were essential to the 
planning stage of the project. The stakeholder analysis was identified by 
the change agent as one of the most important tools as it highlighted 
the concerns of each of the key stakeholders. The level of engagement 
was prioritized according to the power associated with the stakeholder 
as described by Boesso and Kumar  (2009). The change agent viewed 
the SMS and MS as having the greatest power as they controlled key 
resources (e.g. time).  The CM was perceived to have the greatest 
political power followed by the LM and QM, therefore the change agent 
focussed on primarily engaging with these key stakeholders. Effective 
communication can build trusting relationships leading to motivation and 
commitment during change (Elving , 2005). Therefore fact to face 
communication with these powerful stakeholders was an initial priority 
for the change agent.  
 
A communication strategy involving informal meetings to build 
relationships, followed by formal meetings was devised by the change 
agent. As a number of key stakeholders work part-time, attendance a 
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meetings might not always be possible, therefore the strategy also 
involved formal communication via email. There was a pre-existing 
culture of this already in the department to facilitate part-time 
employees and all emails are read at the beginning of a shift. Therefore, 
this system would be used as primary means to inform staff on the 
status of the project in conjunction with monthly meetings.  
 
3.4.1 Building Commitment 
The first step to building commitment involved developing a shared 
vision. A key component of the organisations vision is to 
‘be innovative and responsive to new developments’. Automation in 
microbiology as well as implementing EUCAST guidelines is aligned to 
the hospital vision.  
 
The organisation achieved the accolade of ‘Best Private Hospital’ in 
2014 and is also accredited by JCI, furthermore the microbiology 
department is accredited by INAB to ISO; 15189. The SWOT analysis 
identified that there is a strong commitment to quality across the 
hospital. As outlined in the literature review the change project will 
positively impact on the quality of microbiology results in terms of 
reducing turn-around times (improving patient care), increased ability to 
detect HCAI (improving patient safety), reducing consumables within 
the laboratory (reduced costs), improved reproducibility (improved 
quality of results). The strong commitment to quality was seen as an 
opportunity to align the change to the quality management system 
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already in place to enable the change to gain support from all 
stakeholders.  
 
Resistance can develop when there is lack of trust between the person 
initiating the change and the employees (Kotter and Schlesinger, 1979). 
The vision for change was discussed with the MS, SMS, CM, LM and 
QM individually. This was an opportunity for the change agent to build a 
relationship with each individual involved but also to gauge their 
readiness for change and any resistance (Elving , 2005; Smith, 2005). 
This preliminary conversation was also used to determine 
learning/training needs (see section 3.4.2.2 below). All agreed that the 
vision for would positively impact on the laboratory and there was a 
general feeling of optimism about the change. 
 
The vision was formally communicated at a departmental meeting 
where all relevant pathology stakeholders were present (LM, QM, SMS 
and MS). The alignment to the QMS was highlighted as were the 
proposed benefits to the laboratory. Communicating the role of 
employees and the impact change will have on them is important before 
change is implemented (Elving , 2005). Furthermore Ford et al., (2008) 
suggested that change agents acknowledge resistance, as promotes 
collaboration by stakeholders, which strengthen commitment to the 
project. Therefore, concerns which arose during initial conversations 
and meetings were discussed. There was one recurring concern; the 
ability to balance the new workload with competing demands in the 
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laboratory (quality assurance). Staff were reassured that the workload 
increase during the validation phase would be for a limited period and 
that at the next meeting the implementation plan would be discussed in 
detail and all concerns would be addressed.  Guarantees were made 
that training and competency assessment would only occur when there 
was adequate time available. The commitment of the LM to the project 
was also emphasised by allocation of relief staff for the initial training 
periods.  
 
Lewis (1996) acknowledges that resistance can be beneficial and may 
urge management not to make rash decisions, while Ford et al., (2008) 
suggest that resistance can strengthen the quality of decisions and 
stakeholder commitment.  Feedback was invited at the meeting. Garvin 
and Roberto (2005) note that resisters are often covert and meetings 
which appear cordial may not be. In addition to this the change agent 
did not want shyness, a lack of confidentiality or fear to be a barrier to 
feedback. For these reasons a suggestion box was placed in the 
laboratory which enabled anonymous feedback. The communication 
strategy for the project was also discussed at this meeting.  
 
3.4.2 Determining the detail of the change: 
The tools used during the initiation phase highlighted there was a staff 
skills and knowledge requirement. Training increases willingness to 
participate in change (Smith , 2005). All MS and SMS were informally 
asked about their level of experience with automation and EUCAST 
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guidelines by the change agent. Nobody had any previous experience. 
A significant training program addressing both the VITEK 2 Compact 
and EUCAST guidelines was required. Harden's (1986) ’10 questions to 
ask when planning a course or curriculum’ was used as a basis for 
developing the training programme.  Creating a safe environment for 
learning was also very important and Scheins Eight Steps (Schein, 
2009) for creating psychological safety were also considered (see 
Appendix 6).  
 
The stakeholder analysis highlighted that all were very enthusiastic 
about learning new skills, however there were concerns regarding the 
level of training that would be required and time allocated. To build 
commitment to the project, two staff members with a keen interest in 
AST were invited to become ‘VITEK super-users’. They would receive 
training on the VITEK 2 from bioMerieux application specialists (AS). 
The change agent had previously received this training. The 
participation of these two ‘super users’ was important to build 
commitment to the project (Kotter and Schlesinger, 1979). These 
‘super-users’ were previously the laboratory experts in AST. Therefore, 
if they had a fear of loss of power or position (Schein, 1999 p112) this 
was also an important measure to reduce resistance and learning 
anxiety.  
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The training plan was developed according to the organisations training 
program along with the SMS responsible for training in microbiology. 
Details of the training program are outlined below in Table 1. 
 
Table 1 Training Program Details 
 Method of 
Delivery 
Participants Delivered by 
Introduction to VITEK 2 
Compact: instrument 
overview, analytical 
performance, clinical 
and software 
applications. 
Presentation All 
Microbiology 
staff including 
CM and QM 
 
 
 
bioMerieux 
Application 
Specialist 
Routine use of VITEK 
2 
Hands-on-
training 
All scientific 
staff 
Super-user training; 
troubleshooting, 
maintenance of 
system, use of 
software applications 
and bioArt rules. 
Practical 
demonstration 
2 Super-Users 
Routine use of VITEK 
2 
One-to-one 
hands-on-
training 
All scientific 
staff 
 
 
 
 
Change 
agent 
Overview of EUCAST 
guidelines; 
methodology and 
quality control 
requirements. 
Presentation All scientific 
staff 
Practical application of 
EUCAST guidelines 
One-to-one 
practical 
training 
All scientific 
staff 
 
 
As highlighted in the literature review, a gap analysis between CLSI and 
EUCAST guidelines was required. This was performed by the change 
agent to determine the impact that EUCAST guidelines would have on 
the antibiotic formulary and the reporting of AST results, currently in use 
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in the department. The results of the gap analysis can be found in 
Appendix 7.  
 
A meeting was arranged with the CM and SMS to discuss these 
findings. One week prior to the meeting copies of the guidelines were 
given personally to the CM and SMS. This was important to enable 
them to become familiar with the guidelines. Two days prior to the 
meeting the key points from the gap analysis were emailed to the CM 
and SMS, as well as supporting evidence. Concerns raised by the CM 
during informal conversations (see stakeholder analysis) were also 
addressed and solutions agreed. Suggestions on the most suitable 
antibiotic panels were also given. A more detailed discussion 
surrounding the impact of the new guidelines occurred at the meeting. A 
number of key decisions were reached at this meeting. This quick 
process enabled the change to gain the required momentum to move 
forward. 
 
The literature review highlighted the importance of a clear patient 
centred laboratory report (Cunney and Smyth, 2000). VITEK 2 software 
will generate a large amount of epidemiological information. 
Furthermore EUCAST (2015) guidelines suggest the use of many 
interpretive comments on the laboratory report. This is very useful from 
an infection control and antibiotic prescribing perspective. However 
laboratory reports must remain patient focussed and only comments 
pertinent to individual patient care should appear on the laboratory 
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report. This was discussed with the CM and a rationalised patient 
focussed approach was adopted in the design of the new EUCAST 
interpretative comments. 
 
The literature review also highlighted to potential for the VITEK 2 to 
reduce laboratory TAT. A meeting was organised with the IPCN to 
discuss the potential implications of introducing automation into the 
laboratory. The reduction in TAT for MRSA screening samples was 
welcomed. The potential for the detection of MDRO and the implication 
this would have on the bed-management was also discussed. An action 
plan including a communication strategy for this event was devised by 
the CM and IPCN.  
 
3.4.3 Developing the Implementation Plan: 
To ensure the implementation plan adhered to the change control 
process outlined in the QMS, the change agent worked with the QM.  At 
the first meeting the requirements for the validation plan were 
discussed, along with the change control procedure. Further informal 
meetings took place with the Pathology Manager, CM and the SMS. 
The requirements and concerns of each of these stakeholders were 
discussed in the context of the validation plan. Following this series of 
meetings the validation plan was developed. 
 
Once the validation plan was approved by the QM, the detail of the plan 
was presented at a microbiology staff meeting attended by all of the 
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pathology stakeholders. Trust can be difficult to establish during a 
period of change. However, predictability regarding the change process 
and capability of the change agent to deliver what they promise can 
build trust (McAuliffe and Vaerenbergh, 2006). Even-though change can 
be unpredictable, this plan would act as a blue print for the change 
event. The change agent also shared previous experience of a similar 
change project and the success achieved there. This was also import to 
demonstrate a capacity to deliver change, in particular in an 
organisation where the status-quo was static for many years and 
change might be feared (Reinertsen et al., 2005).  
 
Following the meeting a number of queries emerged surrounding the 
delivery of training. Staff were concerned that if they did not receive the 
training delivered by the AS they would be ‘left behind’ when the 
change was implemented. The change agent understood their concerns 
and the training plan was adjusted. The change agent suggested that 
all staff including the QM and the CM would attend a presentation on 
the VITEK 2 on the first morning of the training. The two agreed ‘super 
users’ would receive two full days of training (incorporating 
troubleshooting) and all other staff members would receive practical 
hands-on training on the instrument by the AS. This measure was 
essential to build commitment to the project.  
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3.4.3 Implementation 
Changes in technology are a major cause of organisation failure and to 
avoid failure staff must be motivated to learn a new technology 
(Appelbaum, 1998). This can be achieved through empowerment with 
the ‘right knowledge, technique and skills to implement the new 
technology’ (Appelbaum, 1998). The first step in implementing the 
change was validating the VITEK 2 instrument, this could not begin until 
formal training on the VITEK 2 instrument had been delivered by 
bioMerieux. All staff members (including part-time staff) were working 
for the two days, firstly to ensure delivery of the microbiology service 
and secondly to attend the presentation and the practical training. The 
training was delivered. The change agent felt that it was important to 
begin the validation process immediately after the training, to ensure 
that the momentum for change was maintained. Feedback was sought 
following the training.  
 
Feedback on the training course highlighted that staff felt that more one 
to one training was needed as did not get enough practical experience. 
This was also the experience of the ‘super-users’. This was a period for 
developing new skills and learning (Schein, 1999) and any unnecessary 
anxiety during this period could result in resistance.  One requirement of 
the validation plan was that all staff would play a role, to ensure staff 
would take responsibility for the successful implementation of the 
project. Their lack of confidence following the initial training did not 
empower them to achieve this. The change agent understood their 
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need for additional training and ensured them that this would be 
provided. Facilitation and support are important measures to reduce 
resistance when anxiety is high (Kotter and Schlesinger, 1979). 
 
Additional training was provided by the change agent. This opportunity 
was also used to introduce bioART rules on the VITEK 2 software. 
These rules were developed by the change agent in response to the 
gap analysis between EUCAST and CLSI guidelines. They prompt the 
user to identify unusual resistance mechanism and also tailor antibiotic 
panels depending on the site of infection. These rules were very 
important during the transition phase to empower staff to recognise 
unusual antibiotic profiles and highlight the key differences of EUCAST 
guidelines.  
 
3.4.3.1 Sustain Momentum 
Unlike other laboratory accreditation standards, accreditation to the 
ISO;15189 standards is applied only to laboratory test methods detailed 
in the scope for accreditation. For this reason, ‘an extension to scope’ of 
accreditation was applied for by the microbiology department, reflecting 
this change project. This was denied by INAB. They required an audit of 
the validation procedures for the implementation of the VITEK 2 and 
EUCAST guidelines, before accrediting these new test methods. This 
was only communicated to the department once the validation had 
commenced. This meant that the new technology and guideline could 
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not be used for reporting results on clinical samples until after the audit 
in May 2015.  
 
The vision communicated to staff to ensure ‘buy in’ to the change 
focussed mainly on the reduction of hands-on time required for 
identification and AST as compared to routine manual methods. Staff 
were informed that once the new processes were validated and training 
complete the new methodology would be implemented immediately. 
This had to change. The change agent feared that the time lag between 
validation and full implementation might have an impact on sustaining 
momentum and commitment to the project. A second concern was that 
the new skills and knowledge learnt would not be used immediately and 
therefore would be lost. This required the implementation plan to be 
reviewed. The author decided to continue as planned with the validation 
but to alter the delivery of the presentations and the training.  
 
The first stage of the implementation plan included a formal 
presentation on the analytical and clinical applications of the VITEK 2. 
This began the ‘unfreezing’ stage of learning (Schein, 1999 p106). The 
vision for change was reaffirmed. The goals of this presentation were to 
disconfirm the current methodologies and create the motivation for 
change as well as creating a safe learning environment. To avoid 
overwhelming people with too much new information a second 
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presentation on EUCAST guidelines was scheduled to be delivered 
during the second week, again with the same goals.   
 
In light of the INAB decision the EUCAST presentation was postponed 
until mid-March when the validation was complete. The validation of the 
VITEK 2 was performed using characterised quality control organisms. 
The original validation plan outlined that each staff member would 
participate in the PQ of the VITEK 2 as part of their competency training 
and this would be performed at the same time as the validation. 
However, the change agent decided, to ensure deskilling did not occur, 
this would now be performed after the validation had been completed. 
This was vital to sustain commitment to the project.  
 
As the duration of the project was now being extended, reviews of the 
project were now more critical (Sirkin et al., 2005). Informal mini-review 
meetings were held in the laboratory every two weeks to discuss the 
status of project, staff concerns and learning they wished to share.  The 
vision of the project was highlighted again at each meeting. The change 
agent also created positive organizational “buzz” through the use of 
stories (based on past experiences with the VITEK 2) to reinforce the 
changes and practices needed to achieve the vision.  This can help 
encourage more rapid adoption of the needed patterns and practices 
(Reinertsen et al., 2005).  
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Managing organizational politics is an essential part of managing 
change (HSE, 2008). Change can increase the prevalence of political 
action (McAuliffe and Vaerenbergh, 2006). The literature review 
highlighted the potential for low staff morale during the implementation 
phase of change (Lam and Jacob, 2012). The change agent was 
conscious that this may reduce commitment, therefore active 
participation and engagement of the key stakeholders was essential 
during this phase. This engagement was described in detail in this 
section. Furthermore, support can be maintained during change through 
negotiation and influencing (McAuliffe and Vaerenbergh, 2006).   For 
this reason the when the QM support for the project was decreasing 
due to competing demands in the quality department, the change agent 
used negotiation to ensure the QM commitment to the project. Finally 
commitment from managers is another key factor to reducing political 
unrest during change (McAuliffe and Vaerenbergh, 2006), the LM 
allocated training resources during the implementation phase and this 
demonstrated managements dedication to the change. However 
management commitment does not always ensure that the organisation 
will embrace the change therefore the change agent worked hard to 
achieve this.  
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3.4.4 Mainstreaming 
3.4.4.1 Making it ‘the way we do business’ 
Processing and reporting of the EQA samples for January-March was 
one of the key objectives of this project. These samples were 
processed on the VITEK 2 for identification and AST. The AST results 
were interpreted according to EUCAST guidelines. The samples were 
processed in parallel with the routine methods. The results from the 
routine methods were reported to NEQAS. There was an error in 
reporting an AST result for January using the conventional methods. 
The routine method failed to detect a resistance mechanism, detected 
by the VITEK 2. This was an opportunity to re-inforce the merits of the 
change project but also to celebrate the achievement of the correct 
results using the new methods.  
 
By Mid-March, all staff had embedded the changes into their daily 
routine. There was an effort made each day for staff to participate in the 
on-going PQ of the instrument. The competency assessments of each 
staff member were also being completed daily. The requirement for 
direct supervision was reduced. An email was sent to all staff directly 
affected by the change highlighting the successes achieved to date, the 
results of the validation and external quality assurance program. 
Outstanding tasks requiring completion before the INAB audit were also 
listed, along with the person responsible for each action. This done to 
maintain commitment to the project and ‘keep employees focused on 
the continuing hard work ahead’ (Garvin & Roberto, 2005)  Finally it 
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was highlighted that support was still available if required (Kotter and 
Schlesinger, 1979). 
3.4.4.2 Mainstreaming; Evaluating and Learning 
This will be discussed in detail in chapter 4.  
3.5 Conclusion: 
The HSE Change Model (HSE, 2008) was chosen for this 
organisational change project for a number of reasons including; it’s 
strong evidence base, previous experience with the model and the 
comprehensive guide and tools available to the user. Change can be 
unpredictable and the change agent cannot control it (Van de Ven and 
Sun, 2011). They can however lead and facilitate change and ensure 
that their selected change model is adapted to fit their organisation (Van 
de Ven and Sun, 2011). Kotter and Schlesinger's (1979) ‘Choosing 
strategies for change’ was used to achieve this by identify and 
managing resistance.  Furthermore components from other models 
were therefore employed by the user (Garvin & Roberto, 2005; Lewin, 
1951, Kotter, 1995) to implement the change, as the HSE model is a 
guiding model which enables the user to draw on other models. 
 
The analysis tools used during the initiation and planning phases were 
essential to determine the drivers and resisters for change as well as 
helping create the vision for change.  Stakeholder analysis was 
performed at the beginning of the project and repeated a number of 
times during the different stages of planning and implementation 
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(Appendix 3). The importance of including all stakeholders from the 
beginning is important. This was highlighted when INAB and bioMerieux 
were not included in the first analysis. It was a threat to the project 
when the change could not be fully implemented for clinical isolates 
before the INAB audit occurred. When this information was received, 
the training and validation plans had to be restructured. This is a key 
strength of the HSE change model as it enables the user to re-visit 
stages of the project. Finally the literature review highlighted many 
issues that required consideration during the planning stage.  
 
Two most important aspects for implementing the change were effective 
communication of the change and empowering staff to embrace the 
change. These two concepts underpinned each stage of the process 
and ultimately ensured that the change was implemented.  
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4.0 Evaluation 
 
4.1 Introduction 
Health care evaluation ‘is an essential part of quality improvement and 
when done well it can help solve problems, inform decision making and 
build knowledge’ (Health Foundation, 2015). This chapter will begin by 
outlining the reasons for healthcare evaluation. Evaluation of the 
change project will be discussed in terms of Donabedians Model of 
structure, process and outcome evaluation (Donabedian, 1968). 
Training evaluation which is relevant to all stages of Donabedians 
Model will be discussed separately, as this was evaluated using 
Kirkpatricks Model (Kirkpatrick, 1979).  
 
Health professionals undertake informal evaluation on a daily basis 
from collecting data, analysing information, comparing interventions and 
making judgements (Koplan et al., 1999). However formal evaluation is 
becoming more important, Ovretveit (1998 p24-27) cities the following 
reasons for healthcare evaluation: 
1. To decide resource allocation 
2. Patients’ ignorance (information for patients) 
3. To improve professionals’ knowledge and decisions 
4. To improve managers’ knowledge and decisions 
5. Because we have to (to justify spending) 
6. To make better informed political decisions  
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Furthermore the Health Foundation (2015) cite that if the evaluations 
are done during the intervention, feedback can be provided on a 
continual basis to enable stakeholders to reflect on and review the 
change in real time. Finally healthcare evaluations may also be required 
for accreditation purposes (Frye & Hemmer, 2012) which was a 
fundamental reason for this evaluation.  
 
Donabedian (1968) published a three phased framework for healthcare 
evaluation: structure, process and outcome. Structure evaluations relate 
to the inputs; equipment, facilities, staff and administration. Process 
evaluations measure the process of how healthcare is delivered and are 
ideally conducted once the project begins. Outcome evaluations 
measure the consequence of an intervention. Outcome evaluations can 
be more difficult to measure, as often the results of an intervention may 
not be seen for a long period of time. Donabedian (1968) warns against 
using any phase of the model in isolation and suggests that a 
combination of all three phases should be used. All three phases of 
Donabedians Model will be used to evaluate the objectives of this 
project. The objectives are shown below in Table 2, as well as the 
means of evaluation. 
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Table 2 Evaluation of Objectives 
Objective Structure Process Outcome 
1. Perform installation, operational 
and performance qualifications 
according to manufactures 
instructions on the VITEK 2 Compact 
instrument. 
X X  
2. Validate EUCAST guidelines disc 
diffusion methodology. X 
  
3. Train all Microbiology Medical 
Scientist to use the VITEK 2 
Compact and EUCAST guidelines 
X   
4. Obtain >95% accuracy in 
cumulative external quality 
assurance scores 
 X X 
5. Standardise consumable costs for 
identification and antibiotic 
susceptibility testing of bacteria. 
  X 
6. Demonstrate a reduction in turn-
around-times for processing 
identification and antibiotic 
susceptibility of bacteria 
  X 
 
4.2 Structure Evaluation: 
Implementation evaluation monitors what is achieved against intended 
objectives and plans. It is a form of audit evaluation, as the information 
collected is compared to the intended policy, standard or service plan 
(Øvretveit, 1998). This type of evaluation was used to evaluate 
objective 1 and 2 (see table 5) of this project. Evaluation of the 
installation qualification (IQ) process is important to ensure that the 
instrument is installed and calibrated appropriately. The operational 
qualification (OQ) ensures that VITEK 2 Compact software and 
hardware perform as expected.  The IQ and OQ specifications are 
outlined by the manufacturer, and were performed by the change agent. 
The IQ and OQ were 100% compliant with the standards outlined by the 
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manufacturer. This structural evaluation of the instrument is a 
requirement of ISO:15189 (2012) accreditation to document the 
equipment is performing as expected.  
 
The performance qualification (PQ) of the VITEK 2 using known quality 
control organisms was another aspect of the structural evaluation of the 
VITEK 2 and was performed over a number of months, involving all MS 
and SMS.  Again an accreditation requirement the PQ evaluated the 
instruments ability to perform identification and AST of bacterial isolates 
characterised by the American Type Culture Collection (ATCC) a non-
profit organisation over a 25 day period.  Any deviations from expected 
results were investigated.  There was one unexpected biochemical 
result achieved with one bacterial strain Enterococcus casseliflavus 
ATCC 700323. Troubleshooting identified a problem with the primary 
culture media. This was amended and the QC testing was repeated. 
The correct results were obtained, see Table 3 below.  
 
The second objective to validate disc diffusion methodologies according 
to EUCAST guidelines, again this required a structural evaluation of the 
antibiotic discs, culture media and equipment used in manual disc 
diffusion. EUCAST prescribe tightly controlled reference ranges for QC 
strains to ensure compliance with EUCAST methodology. Again a 25 
PQ was performed using five ATCC strains, testing 34 antibiotics each 
65 
 
day. Evaluation of these results with the expected ranges was 100% 
compliant with the standards, see Table 3 below. 
 
Table 3 Structure Evaluation Results 
Structure Evaluation Target Achieved/ Date 
IQ Fully compliant with 
manufacturer’s instructions. 17/1/2015 
OQ  
23/2/2015 
PQ VITEK 2 113 tests daily over 25 day 
period, fully compliant with 
ATCC characteristics, 
EUCAST guidelines and 
manufacturer’s instructions 
20/3/2015 
PQ EUCAST 34 tests daily over 25 day 
period, fully compliant with 
EUCAST guidelines. 
27/3/2015 
 
4.2 Process Evaluation: 
PQ also involved process evaluation, of how the new laboratory 
processes are being implemented. The structural aspect of PQ was 
discussed above. This aspect of evaluation focused on the new 
elements of the change process (Frye and Hemmer, 2012) and involved 
the use of EQA and laboratory stored bacterial strains. The VITEK 2 
Compact enables the identification and AST from Columbia Blood Agar. 
According to manufacturer’s instructions if bacteria are tested from 
other media, this must be validated by the user. Therefore identification 
and AST on these characterised bacterial isolates was performed on 
the VITEK 2 Compact from a wide variety of microbiology culture media 
and on blood agar. The results were compared. Comparisons between 
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the identification using conventional and automated methods could also 
be performed. However comparisons of AST results was not performed, 
as there was a different methodology and guideline used, so this 
comparison would not be suitable.  
 
Evaluation of these results was based on criteria described by Eigner et 
al., (2005). There are five different categories for comparing MIC 
values, see Table 3 below. Very minor errors are expected, due to test 
variation however minor, major and very major errors are unacceptable 
and warrant further investigation (Eigner et al., 2005). 
Table 4a  MIC Category Agreements (Eigner et al., 2005). 
Agreement MIC agreement 
Interpretative category agreement 
(very minor error) 
MICs are different by >1 dilution 
but are in the same interpretative 
category. 
Minor error Susceptible or resistant by 
reference method and 
intermediate by test method OR 
intermediate by reference method 
and sensitive or resistant by test 
method 
Major error Resistant with test method and 
susceptible by reference method 
Very major error Susceptible by test method and 
resistant by reference method 
 
Table 4b MIC Category Agreement Results (Process Evaluation) 
MIC Category Agreement Percentage of Results 
Agreement 94% 
Very minor error 6% 
Minor error 0% 
Major error 0% 
Very major error 0% 
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There were 570 individual antibiotic tests performed as part of the PQ. 
From this there were no minor errors, major errors or very major errors. 
There were 34 very minor errors, with interpretative category 
agreements but where MIC values were different. These errors would 
not have an effective on the result reported or on patient treatment.  
 
This PQ was also used for training evaluation. Trainees performed the 
test method (variety of culture media) and the change agent performed 
the reference method (blood agar). This was satisfactory process 
evaluation result as it demonstrated that the identification and AST 
process was achieving accurate, reproducible results independent of 
the user or culture media.  
 
The total information gathered when structure, process and outcome 
are evaluated simultaneously may be greater than the mere sum of all 
three (Donabedian, 1968). EQA was used to evaluate the structure, 
process and outcome of this change project. EQA scores were 100% 
accurate for the duration of the PQ. This further demonstrates the 
accuracy of the new method and will be discussed further below.  
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4.3 Outcome Evaluation: 
Performance indicators (PIs) are an invaluable tool that contribute to 
performance monitoring processes (HIQA, 2010). PIs are generally 
introduced in an organisation to foster a change in the quality processes 
(Perera et al.,  2007). It is essential that appropriate PIs are selected to 
deliver reliable, reproducible and meaningful data. HIQA (2010) have 
developed criteria for selecting PI and they include a sound evidence 
base, sensitivity, timeliness, feasibility and relevance. PIs can be useful 
for the measurement and evaluation of a change as they provide a 
basis for collecting evidence to monitor the success of a particular 
program (Koplan et al., 1999). However it is important that PIs are not 
solely used to evaluate the success of a program, because other factors 
may be influencing the indicator and this may be beyond the scope of 
the initiative (Koplan et al., 1999).  
 
The Royal College of Pathologists (2011) suggest that all clinical 
laboratories participate in an EQA scheme. The microbiology 
department participates in the UK NEQAS (United Kingdom National 
External Quality Assessment Service). Monthly samples are sent to the 
laboratory for testing, results returned to NEQAS, where they are 
collated and compared to other laboratories. Results can be used as a 
means of evaluating the change program. However as noted by Koplan 
et al., (1999) other factors beyond the scope of the initiative can also 
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impact on the PI such as culture media, environmental conditions 
(incubators/temperature/atmosphere) and personnel in this context.   
 
EQA scores are used as a PI in the organisation and satisfactory results 
are set at a cumulative level of 95% for the year by the QM. Any 
deviation from expected results is non-conformance and investigated 
thoroughly. Figure 3 illustrates the EQA results for the period of the 
study (Jan-March) using the conventional methods versus the EQA 
results achieved with automated identification and AST interpreted 
using EUCAST. The 95% cumulative target score is also highlighted.   
Figure 3 External Quality Assurance Results; Comparison of Manual 
and Automated Methods 
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this period, relating to the detection and interpretation of AST results for 
MDRO. NEQAS reported for these tests that ‘incorrect results were 
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more common among participants using manual methods’ and ‘more 
common among participants using CLSI guidelines’.  
 
Another PI in the department is TAT. There are a number of variables 
surrounding TAT in microbiology; these include specimen type, 
organism isolated and AST profile of the organism. For example the 
TAT for a urine culture with no pathogens isolated is only 16 hours. 
However if there is a pathogenic bacteria isolated, the time increases by 
a further 20 hours for wild-type organisms with little or no antibiotic 
resistance. If there is an unusual antibiotic resistance profile, this must 
be investigated and the TAT is extended again by a further 24 hours, 
totally 60 hours. This is further complicated for other more complex 
sample types such as those from normally-sterile site. Generally 
bacterial loads are so low from these sites, there are insufficient 
bacterial colonies for identification and AST until after a preliminary 
incubation time of 48 hours. For more fastidious organisms organism 
identification can also take 48 hours. These factors had to be 
considered when measuring TAT’s for this evaluation. The routine data 
collected in the department for TATs was insufficient for this evaluation 
as the complexity of the samples is not addressed.  
 
To ensure that the most appropriate data was used to evaluate the 
TAT, TATs for bacterial cultures which were tested as part of the PQ 
were recorded. These were bacterial strains which were previously 
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isolated in the department and were tested using the conventional 
manual methods. TATs were available on the laboratory information 
system for each isolate. The TAT for each isolate using the new 
methods was also recorded. Due to the complexity of bacterial strains, 
gram positive and gram negative isolates were further classified into 
multi-drug resistant isolates and more routine ‘wild-type’ strains. This 
enabled a true evaluation of the data.  
 
This is an output evaluation and illustrates a limited amount of data. For 
an outcome evaluation demonstrating the relationship between TATs 
and the use of the VITEK 2 Compact, the methodology for TAT data 
collection in the laboratory must be amended.  TAT data must be 
collected on both specimen type and also the phenotype of the bacterial 
strain isolated. This would allow a true outcome evaluation. Figure 4 
highlights the decrease in TAT achieved when using the VITEK 2 in 
comparison to manual methods. This is significant (> 16 hours, 
difference of a working day) for the isolation of multi-drug resistant 
bacteria (MRSA and gram negative). The most valuable aspect of this 
data is the TAT for all organisms irrespective of complexity, have the 
same TAT when using the automated system.  
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Figure 4 Comparison of Turn-Around Times for Manual versus 
Automated Methods 
 
 
Economic evaluations are the second most common types of 
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evaluations involving cost-description relate to inputs (structure). A cost 
evaluation was performed to compare the cost of traditional 
identification and AST with the new automated methodology. Cost 
reductions were estimated based on the number of identification and 
AST tests performed in 2014.  The cost spent on consumables relating 
to the identification and AST of bacteria, during 2014 was calculated. 
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on estimates of the complexity of the organism isolated. As illustrated 
above in relation to TAT, antibiotic resistant organisms require further 
antibiotic tests, which increase the TAT but also the cost.  
 
For the reason outlined above, consumable costs were calculated for 
45 isolates which were included as part of the PQ. The exact cost of 
processing each isolate using conventional methods and the VITEK 2 
Compact was calculated. This allowed a direct comparison of costs. 
Again the results are illustrated based on the complexity of the isolates 
i.e. multi-drug resistant versus wild-type strains. See Figure 5 below. 
Figure 5 Consumable Cost per Isolate for Identification and 
Antimicrobial Susceptibility Testing 
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Figure 5 illustrates the consumable cost irrespective of the organism 
identification and antibiotic resistance profile. The cost for identification 
and AST is standardised using the automated method. It also illustrates 
the variability of costs relating to the isolation of resistant isolates using 
manual methods.  
 
The data represented here is for a limited period and only represents 
consumable costs. Additional costs associated with the interface 
connecting to the laboratory-information system, maintenance contracts 
and validation are not included. The interface cost is a one-off payment 
of €12,000 (interface maintenance is covered by an existing contract) 
and the VITEK 2 annual maintenance contract is €1400. Some 
consumables were provided free of charge for validation, the additional 
cost to the department for validation consumables is €765.44. The 
projected savings using the 2014 data as outlined above is €9299, this 
means that within two years the capital invested in the instrument 
validation and interface would be saved along with the cost of the 
maintenance contract for two years.  
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4.4 Training Evaluation: 
Training/learning needs analysis was performed during the planning 
stages to determine the specific training requirements of the training 
programme. The training programme was then developed and it 
involved a number of stages, as previously discussed above (Table 1). 
Training evaluation is essential to determine if the delivery of the 
training program was successful in achieving its’ objectives. Kirkpatricks 
Model was chosen to evaluate the training program (Kirkpatrick, 1979). 
 
Before beginning a training evaluation program it is important to identify 
the purpose of the evaluation (Phillips, 2012 p. 53). There were three 
main reasons for training evaluation in this project: 
1. To identify any deficits in the training program. Identifying 
problems at an early stage would allow the change agent to alter 
the training program to ensure training objectives are achieved.  
2. To improve the learning process for future training on the VITEK 
2 Compact and EUCAST guidelines. 
3. To provide evidence that employees are trained on the use of the 
VITEK 2 and EUCAST guidelines (INAB and legal obligation).  
 
There are four phases to the Kirkpatrick Model. The first phase is the 
‘Reaction’ phase, which seeks to measure satisfaction with the training 
received. There is debate as to the effectiveness of this phase of 
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Kirkpatricks model as it is based on participants’ perceptions. However, 
in this project it was used to gauge the trainees’ reaction to the initial 
training provided. A number of different approaches can be used to 
evaluation this stage of the training. A quantitative questionnaire using a 
Likert-type rating scale is beneficial to determine the attitudes to the 
training provided (Garavan et al., 2003). However the change agent 
was trying to establish trusting relationships with colleagues, therefore 
this was used as an opportunity to meet everybody face to face and 
gauge feedback on the training received. Feedback during the 
preliminary stages of training highlighted that there was a requirement 
for more practical training and supervision. Also desk-aids were 
requested for the workstation, these contained the key information from 
the SOP.  
 
The second phase of Kirkpatricks Model is ‘Learning’ and is concerned 
with measuring actual learning achieved. In the accredited clinical 
laboratory there is a requirement to demonstrate and document that 
Medical Scientists are trained and competent to perform specific tasks 
(Burnett, 2002). Learning is initially assessed in the laboratory by 
observing the trainee performing the task under-supervision. This part 
of the training is usually repeated a number of times until the trainer is 
satisfied that the trainee is competent. The trainee must then perform a 
written competency assessment. The written competency assessment 
is important, as it is an objective measure of the trainees’ competency, 
as opposed to the initial observations with are a subjective view of the 
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trainer (Garavan et al., 2003). ISO:15189 standards also outline that  
competency assessments must be available in employees training 
documents.  
 
The training SOP in the organisation states that employees must 
acquire 100% in competency assessments. There were two different 
written assessments completed as part of the training evaluation. Firstly 
the ‘super users’ had to complete a written assessment for bioMerieux 
to achieve their certification. Secondly all users completed a written 
assessment which consisted of 10 questions regarding the EUCAST 
guidelines and AST and 10 questions about the operation and 
maintenance of the VITEK 2 Compact. 100% compliance was achieved 
by each participant.  
 
The third phase of Kirkpatrick’s Model is ‘Behaviour’, which involves 
observing changes in the trainee’s behaviour and performance. It poses 
the question, were the skills learnt transferred to the job. This phase is 
commonly used in pathology for training. Examination/witness audits 
are used to determine if the trainee is has a good understanding of the 
procedure and is performing specific tasks according to the guidelines 
in place (Burnett, 2002). Witnesses audits were conducted by the QM to 
determine if the process being performed by the auditee was as 
outlined in the SOP and the guidelines. The results of the witness audits 
were 100% compliant with the SOP and guidelines. However the audit 
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did raise an observation that the SOP did not give detailed instructions 
on the QC procedure.  This was raised after the first trainee was 
audited, the procedure was amended to include greater detail. Further 
witness audits were conducted against the amended SOP.  
 
The fourth and final stage of Kirkpatricks Model is ‘Results’ and involves 
measuring the business impact of the training. The financial impact of 
the project was discussed above. Another business impact is on quality 
of laboratory results. The literature review highlighted that EQA 
schemes can be used not only for process evaluation (as previously 
discussed) but also for competency assessment of the participant. Each 
trainee was required to complete at least one EQA sample, post-
training. This enabled the evaluation of the impact of the training on the 
overall quality performance of the laboratory (Kahlmeter and Brown, 
2002).  
 
Table 5 below shows a summary of the training evaluation results. 
Kirkpatricks Model (1979) was chosen for training evaluation as levels 
two and three are aligned with the training requirements of the QMS in 
the department. However, there are a number of limitations associated 
with this model. One limitation that all of the information and skills 
learned during training and known immediately may not be retained 
after one month (Mann, 1996). Therefore the written competency 
assessments and witness audits were conducted in April 2015, over a 
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month after the completion the formal training. Frye and Hemmer 
(2012) criticise the model as it does not take learning motivation and 
variable entry levels of knowledge into account. In this context, entry 
levels of knowledge was not relevant as previously discussed, however 
learning motivation may have had a positive impact on the evaluation. 
This will be discussed in further detail in Chapter Five.  
Table 5 Summary of Training Evaluation Results 
Kirkpatrick 
Level 
Assessment Results Date 
Completed 
1. 
Reaction 
Verbal Feedback 
following training 
Feedback received 
and program altered 
as appropriate. 
20/3/2015 
2. 
Learning 
Written competency 
assessment 
100% compliance. 20/3/2015 
3. 
Behaviour 
Witness audits 100% compliance. 
Observation that there 
was insufficient detail 
in SOP. SOP was 
updated and re-
audited.  
24/4/2015 
4. Results EQA Results 100% EQA scores for 
Jan-April.  
24/4/2015 
 
4.5 Conclusion: 
The fundamental purpose of evaluation is provide evidence for decision 
making (Phillips, 2012 p.62). Both formative (used to assist in program 
development) and summative evaluations (a summing up of the overall 
effect of an intervention) were used in this project (Health Foundation, 
2015). Stufflebeam and Shinkfield (2007) note that the same data may 
be used for both types of evaluations, as occurred here. Formative 
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evaluation was used during the implementation and mainstreaming 
phases of the project, particularly in relation to the training evaluation. 
Training evaluation results such as feedback and competency 
assessments were reviewed during the implementation stage. This not 
only enabled problems to be detected and changes to be made during 
the project but also facilitated the acknowledgement of mini-success 
when positive results were achieved.  
 
Summative evaluation was used at the end of the project to define the 
benefit of the change in terms of cost and quality. An executive 
summary report was compiled consisting documenting that objectives 
were achieved and the overall worth of the project in terms of 
investment and quality improvement. This was presented to 
stakeholders at the Pathology Quality Meeting as well as at a 
Microbiology Staff Meeting. The cost savings, improvement in EQA 
results and audit results were discussed in detail. The limitations of the 
evaluation were also highlighted. First, the requirement of an 
independent external audit (INAB) to ensure that all of the processes 
and documentation are compliant with the QMS, ISO:15189 and 
EUCAST guidelines. This will be was an important aspect of this 
evaluation.  Second, the importance of on-going proficiency testing to 
monitor the impact of new methodologies and competency of trained 
staff was discussed. Third, the requirement to develop a new method 
for calculating TATs, which addresses the complexity of bacterial 
isolates but also specimen type was highlighted. Finally the change 
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agent discussed the limited cost evaluation that was performed. The 
need for on-going monitoring of consumable costs was emphasized to 
truly measure the impact of the change initiative.  This outcome 
evaluation may take a number of year to finalise but will be an important 
learning tool which can be applied to investment in other forms of 
automation.  
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5.0 Discussion 
 
For successful leadership during change the leader must separate from 
the past, create a sense of urgency, develop structures to 
communicate, involve people and be honest, reinforce and 
institutionalise change (Kanter, 1992). This chapter will focus on the 
successes of the project and also threats to the implementation of the 
change. The impact of the project will be discussed in terms of 
behaviour, cultural and personal impact (structural impact will not be 
discussed, as roles and responsibilities were not affected by this 
change). Finally the contribution of this project to the literature on 
automation in microbiology and recommendations for future initiatives 
will be discussed.  
 
5.1 Successes of the Project 
Communication of the vision should be continuous and sustainable to 
ensure that employees are clear about where the organisation is going 
(Kotter, 1995). Involving all stakeholder, linking the vision to shared 
values or guiding principles and constant repetition of the vision in a 
clear goal centred way are a number of ways to achieve commitment to 
a vision (Gill, 2011 p124-130). All stakeholders were engaged in 
creating the vision, the vision was linked to the quality values and 
mission statement of the organisation and every opportunity was taken 
(meetings, emails and informal discussions) to share the vision and 
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highlight the goals. This built commitment to the project and generated 
the motivation for learning (Smith , 2005; Ford et al., 2008). 
 
The training plan was successfully implemented. EUCAST guidelines 
were used by trainees appropriately as demonstrated by the EQA 
results and audits. Feedback received during and after the different 
stages of the training program ensured that training remained focussed 
on the needs of the trainees. Additional training was introduced based 
on feedback, as well as ‘desk-aids’ in the AST area of the laboratory 
highlighting the key points of the guidelines. The structure of this 
training program can be adapted for future change initiatives in the 
department.  
 
5.2 Threats to the Project: 
The initial stakeholder analysis did not include INAB. This was a 
significant threat during the implementation stage of the project. The 
implementation plan and training plans were re-structured to ensure 
that momentum was sustained. This reflects that change agent must 
reflect and adapt (Van de Ven and Sun, 2011) during organisational 
change. The change agent was honest and accepted responsibility for 
the oversight when communicating with the stakeholder, to maintain 
trust and integrity (Ford et al., 2008). This was also a key learning 
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experience and will ensure that INAB will be considered in further 
change projects within the department.  
 
Change agents can be internal or external to an organisation. There are 
benefits to using an external change agent as they are not bound by the 
culture, politics, or traditions of the organisation. Therefore, they are 
able to bring a different perspective to the situation (Lunenburg, 2010). 
However external change agents can lack an understanding of the 
organisations culture, operating procedures, and personnel which is a 
benefit of using an internal change agent (Lunenburg, 2010). As 
previously mentioned the change agent was new to the organisation 
and during the initial stages of the project was effectively an external 
change agent. The change agent was able to bring a new fresh 
perspective to the department, along with the commitment and 
motivation to create change. However this was balanced with a limited 
knowledge of the culture ‘the way things were done’, power and politics 
of the organisation.  Therefore change agent had to build trusting 
relationships to build an alliance for change (Smith , 2005) and also 
navigate the power and politics of the organisation (McAuliffe and 
Vaerenbergh, 2006).  
 
In the organisation where the author previously worked, the power 
structure was very different. There was two main types of power as 
described by French and Raven (1959) in the department; expert power 
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and legitimate power. It was a number of months before the change 
agent recognised that there was coercive power used by one of the key 
stakeholders. The change agent required the stakeholder’s co-
operation to complete the project on time.  
 
The change agent was unfamiliar with the power base within the 
organisation and this became a threat to the time-line of the project. 
The QM was required to approve each stage of the validation and 
change process. The change agent was not aware of this until the 
project was in the implementation stage. The QM was extremely busy 
preparing for the upcoming INAB audit and also introducing a major 
change in the QMS (electronic document management system Q-
Pulse).  The change agent had extensive experience with Q-Pulse. The 
change agent negotiated with the QM and agreed to become involved 
in the training of Q-Pulse users. In return the QM allocated additional 
time to this change project (transactional leadership). The use of 
negotiation and agreement be effective to reduce resistance but can be 
expensive (Kotter and Schlesinger, 1979). It put added strain on the 
change agent’s time but ensured the project was completed on-time.   
 
5.3 Successes and Limitations of the Evaluation: 
Implementation evaluation measures what is achieved against intended 
objectives and plans. The IQ, OQ and PQ were all evaluated against 
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the intended results and validation plan. The results from this evaluation 
were that the IQ, OQ and PQ were all conducted according to the 
validation plan and that the intended results were all achieved. The 
successful results for this evaluation are important as they demonstrate 
the ability of the department to implement a major change within a 
defined time-scale and according to the perimeters outlined in the 
project plan. Future change initiatives in the laboratory could be based 
on this successful plan. This evaluation is also important from an 
accreditation perspective as it documents that, in this department, the 
VITEK 2 Compact is operating as intended by the manufacturer and 
EUCAST guidelines are being implemented as outlined by EUCAST.  
 
The cost evaluation demonstrated a cost saving €2.90 for gram positive 
bacteria, €3.86 for MRSA, €4.01 for gram negative bacteria and €10.48 
for MDRO (gram negative) based on consumables. The evaluation also 
demonstrated that within two years of the project the savings made on 
consumables will fund the capital investment made in the project 
(interface, validation and maintenance). However, as discussed in 
Chapter Four, there are many limitations associated with the cost 
evaluation performed. It will be difficult to perform the true economic 
evaluation of this change, as the use of cash-flow or profit and loss for 
the department would be based on the assumption that there have 
been no other changes in the department during the period of 
evaluation. This cannot be assumed as there are always confounding 
factors such as seasonal outbreaks, changes in culture methods or 
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even increase or decrease in the cost of other consumables. This is 
also reflected in the literature as other efforts to evaluate the cost 
implications of VITEK 2 have also been based on consumable use as 
described in this evaluation (Berke and Tierno, 1996; Robinson et al., 
1995).  The evaluation however did demonstrate that consumable costs 
are standardised irrespective of organism complexity when the VITEK 2 
is used for the identification and AST of bacteria.  
 
According Kirkpatrick (1979) before and after learning should be 
measured. The change agent did not want to expose or embarrass staff 
by imposing a ‘pre learning’ assessment. Trainees were asked about 
their level of knowledge and experience with the new processes 
informally before the training plan was developed. The change agent 
felt this was most appropriate in this context. Also as a tool to build 
trusting relationships the change agent felt that the reaction to the 
training would be best evaluated by having an informal discussion with 
each trainee individually. This enabled the change agent to understand 
the requirements of the trainees better and build a rapport with them. 
However this may be a limitation, as there is no formal record of the 
reaction to the training and there is a possibility that trainees did not feel 
comfortable giving negative feedback face-to-face.  
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5.4 Project Impact: 
5.4.1 Behavioural 
The results from the PQ and EQA samples, as well as the witness 
audits of trainees demonstrated that the training program was 
successful and MS behaviour has changed. However the proficiency 
data is limited, therefore the on-going evaluation of EQA results will be 
important to demonstrate a sustained impact on behaviour. Also all of 
the evaluation was performed in the weeks following the training 
therefore further witness audits will be required to ensure that old 
processes are not re-introduced.  
 
As discussed in the literature review there can be an increase in 
laboratory analytical errors when introducing new behaviour (Lam and 
Jacob, 2012), furthermore competency assessment may not detect 
incompetency (Sharp & Elder, 2004) therefore it will be important to 
monitor non-conformances in the department. This will yield further 
information on the success of the training on changing behaviour.  
 
5.4.2 Personal 
The author reflected considerably during this project. One theme of 
reflection was the different leadership styles employed through-out the 
change initiative. The change agent was new to the organisation and 
therefore was in a position of being both an internal and external 
change agent. 
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There are a number of ways for a new leader to proceed when they 
come from outside an organisation. They can destroy the existing 
culture, fight the existing culture, give in to existing culture, or evolve the 
culture by initially adapting enough to figure out how to get things done 
and then gradually impose new behaviours (Shein, 1999 p4-5). The 
change agent tried to evolve the existing culture by building on the 
commitment to quality healthcare and gradually changing the culture in 
the department to embrace new skills and knowledge.  
 
Transformational leaders; foster a learning environment, actively listen, 
present new ideas and information. They motivate followers and 
communicate confidently a clear vision aligned to the values of the 
organisation (Gill, 2011). To build trusting relationships and gain 
support for the project, the change agent spoke to each stakeholder 
individually and employed a consultative approach to build the vision. 
Once the vision aligned to the values of the organisation was developed 
it was communicated relentlessly.  
 
Popper and Mayseless (2003) report the relationship between 
transformational leadership and empowerment as encouraging 
followers to think independently and raising their competence, self-
worth and self-management. A participative leadership style was 
chosen to aid empowerment and commitment to the project. However, 
the author struggled to empower MS and SMS to think independently. 
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The change agent was frequently asked technical questions, even after 
competency assessments had been successfully passed. This raised 
many questions. Was the training evaluation flawed and failed to detect 
training deficits? Was there resistance emerging? Or was it simply a 
lack of confidence? The change agent reflected that it may be a lack of 
self-confidence compounded by a tendency of the change agent to 
micro-manage situations. The change agent would give direction on 
how to problem solve or give the answer (transactional leadership) 
rather than using open and probing questions (transformational 
leadership) (Gill, 2011 p85).  A conscious effort was made to leave the 
vicinity of the VITEK 2 workstation when it was in use by other staff 
members. When questions were asked, the change agent encouraged 
trainee problem solving. This was challenging for the change agent but 
very important, as MS are required to work independently outside 
routine hours. This highlighted the limitation of the training evaluation as 
‘self-confidence’ was not measured. This was a valuable learning 
experience for the author. 
 
Females display a greater tendency towards transformational 
leadership and offer contingent reward behaviours. While males were 
show to display more components of transactional leadership (Eagly et 
al., 2003). The author a female change agent also offered contingent 
rewards to MS. Staff were praised when they demonstrated self-
direction, independence and when performance measures were 
achieved. Gradually confidence and competence grew and this 
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reinforces the finding by Quinn and Spreitzer (1997) that truly 
empowered people have a sense of self-determination (they are not 
‘micro-managed’) and they are confident about their ability to do their 
work well. This in-turn further motivated staff as it relates to Maslows 
hierarchy of needs and ‘self-actualisation’, the highest level of 
motivation (Maslow, 1943).  
 
5.4.3 Cultural Impact: 
Barrow (1993) reported there is a link between process improvement 
and organisational learning. During this change project, employees 
welcomed the opportunity to develop new skills and gain knowledge. 
The culture of the ‘learning organisation’ was embraced. There are five 
focuses of the learning organisation (Wang and Ahmed, 2003); Table 4 
below shows how each one of the five focuses has been adopted by the 
department.  
Journal clubs and educational workshops have been introduced into the 
organisation and will be held once a month. There is a renewed interest 
in continuous professional development (CPD) and staff are motivated 
to attend external meetings (‘self-actualisation’) (Maslow, 1943). This 
unexpected outcome however may have resulted in a positive bias on 
the evaluation of training (Frye and Hemmer, 2012). 
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Table 6 Focuses of the Learning Organisation (adapted from Wang and 
Ahmed, 2003) 
Learning Focus Implementation of Focus 
 
Individual learning Training and development of skills 
for the use of VITEK 2 and 
EUCAST guidelines. 
Process or system learning Enhancement of problem solving 
and troubleshooting for routine 
work 
Culture or metaphor Create a learning culture; ‘every 
worker is a knowledge worker’. 
Support and encourage staff to 
attend internal and external course 
and share their learning 
experiences. Creation and 
maintenance of a learning culture 
for the future- Journal clubs and 
workshops.  
Knowledge management Strengthen knowledge bases-
presentation of information 
acquired at external scientific 
meetings to all staff on return- 
journal clubs and workshops. 
Total Quality Management Learning from non-conformances 
and incidents was already in place 
in the department. This again 
highlights the strong commitment 
to quality. 
 
5.6 Contribution to practice/theory 
As outlined in the literature review by there is a need for further 
investigations surrounding the impact reduced TAT (as a result of the 
VITEK 2) have on patient care. TAT are reduced for the detection of 
HCAI as illustrated by the TAT for MRSA in this project. The 
identification and isolation of patients with HCAI is a primary goal of 
infection prevention and control. Reducing TAT’s has the potential to 
reduce the number of contacts an MRSA positive patient will have while 
their MRSA status is investigated.   
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Healthcare evaluations are important to provide evidence that 
investment in human resources or capital projects has delivered the 
desired financial outcomes (Health Foundation, 2015). The literature 
review highlighted the VITEK 2 is associated with cost reductions in the 
region of £0.70 per isolate for identification (Mulatero et al., 2011). This 
is significantly lower than the cost savings outlined in this project. This 
study was conducted in a small microbiology department, providing 
both adult and paediatric services, with 60% acute admissions.  For this 
reason the department stocks a large amount of reagents. Many of 
these items are used infrequently. Reagents infrequently used are 
associated with more waste and generally have a higher cost 
associated with. Therefore the cost savings reported here may be 
associated with smaller laboratories only and is important finding, 
requiring further investigation. Furthermore the impact of cost 
standardisation on budgeting and planning in microbiology has not been 
reported in the literature. The data presented here demonstrates the 
association between the VITEK 2 and consumable cost reduction and 
standardisation. The data is limited and further evaluation involving a 
greater number of samples and input from the organisations’ finance 
department would be required to explore these findings further.  
 
5.7 Conclusion 
The HSE change model (2008) guided this change successfully and the 
project management tools employed during the initiation phase were 
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vital to create the vision but also to develop the implementation plan 
involving all stakeholders. In addition to the project management tools, 
stakeholder engagement and effective communication throughout the 
change process were vital to ensure commitment and motivation to the 
change. If the change agent were to do this project again these aspects 
of the process would be repeated. However the change agent would 
change a number of things. The author would be more conscious to 
include all stakeholders in the analysis from the beginning. The change 
agent would be more politically astute (Clarke and Meldrum, 1999) to 
identify powerful stakeholders. Finally the author would be more aware 
of the impact leadership style and micro-management has on 
empowering colleagues during the change process.  
 
In addition, there are a number of recommendations the change agent 
would make for undertaking a similar project if there were no time 
constraints or resourcing issues: 
i. Involve the finance department to enable comprehensive 
financial analysis to determine the true impact automation has on 
costs. 
ii. Obtain base-line data for the amount of scientific hands on time 
required to perform identification and AST using manual versus 
automated methods. Demonstrating a significant reduction would 
be an important outcome and may enable management to 
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achieve buy-in from staff to expand the service offered by the 
laboratory.  
iii. Currently TATs are defined by sample type irrespective of 
whether bacteria are present or not resulting in a wide range for 
TATs.  Define TATs for identification and AST before 
commencing the project, would enable baseline data to be 
measured and concrete TATs to be established.  At the 
organisational level, without this, the impact of reducing TAT (as 
reported here) will not be significantly acknowledged.  
iv. Auditing prescribing practices before introducing EUCAST 
guidelines would also be beneficial to determine the effect 
changing guidelines has on the prescribing data.  
 
In conclusion, for successful organisational change there must be 
collaboration (Elwyn and Hocking, 2000) and powerful communication 
(Appelbaum, et al., 1998). Organisational change must result in quality 
improvements (Elwyn and Hocking, 2000). When change is lead from 
the bottom up the change agent must have a clear vision and ambition 
(Clarke and Meldrum, 1999), furthermore the change agent must 
engage with stakeholders, acknowledge perceived resistance and use it 
to strengthen the project (Ford, Ford, and D’Amelio, 2008). In this 
context the change agent strived to embrace all of these pre-requisites 
for organisational change and reaped the rewards with a successful 
change initiative as demonstrated by the quality improvements 
achieved.  
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Appendix 1: SWOT Analysis 
 
 
  
Strengths 
Experienced Staff 
Commitment to quality across 
organisation. 
Accreditation to ISO;15189 and 
JCI standards. 
Team work. 
Weaknesses 
No automation in the department. 
No history of continued 
professional development (CPD). 
Very little extra capacity in the 
laboratory. 
 
 
Opportunities 
Increase laboratory capacity to 
offer new tests. 
Quality improvement. 
Comparison with other 
laboratories. 
Decrease stock held by the 
department thereby reducing 
consumable cost. 
Development of new skills and 
knowledge. 
Improve ability to implement 
National Guidelines.  
 
 
Threats 
HIQA Audits: National/European 
Guidelines not implemented; 
insignificant implications for 
infection control.  
 
Consolidation of laboratory 
services to another site within 
organisation. 
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Appendix 2: Force Field Analysis 
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 Forces 
AGAINST 
Change 
Score 
 
3 
 
 
Improved quality   Staff fearful of new  
technology 
2 
 
3 
 
 
Decreased turn-
around time 
  Environmental 
impact,  
Reduction in lab 
space 
1 
 
3 
 
 
Increased capacity 
for further tests 
  Disruption in early 
days 
1 
 
3 
 
 
Automation will 
enable 
Implementation of 
National 
And European 
Guidelines 
  Increased 
workload during  
the transition 
3 
 
1 
 
 
Competitors are 
using the  
technology 
  Resistance for the 
sake of it 
1 
3 
 
 
 
Strong management 
buy-in 
  Staff do not have 
the skills or 
knowledge 
required to 
implement the 
change 
3 
3 
 
 
 
Accreditation- 
traceability 
    
 
3 
 
 
Staff keen to upskill     
 
3 
 
 
Reduce cost of 
consumables 
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Stakeholder Job Role Project Role Interest* Why?** Impact* Responsibility* Readiness* Capacity* 
Consultant 
Microbiologist 
Clinical lead for the 
department 
Clinical decision 
maker for the 
implementation of 
guidelines. 
Power and 
influence to ensure 
that appropriate 
resources are 
allocated to the 
project (E/V). 
High (E) Impact on 
quality of 
results 
reported. 
 
High 
May result 
in an 
increase of 
queries due 
to 
interpretive 
comments. 
Medium (E) 
Responsible for clinical 
input. 
Medium (E) 
But nervous 
about the impact 
EUCAST will 
have on his 
workload. 
Medium (E) 
 
Medium (V) Automation 
will not have a 
direct impact 
on day to day 
workload but 
will enable 
more 
standardised 
reproducible 
results 
(improved 
quality) 
Low (V) Low (V) 
 
Medium (E) 
Very excited 
about the 
prospect of 
automation.  
Competitive 
advantage over 
other labs in the 
group. 
 
Low (V) 
Very little knowledge of 
VITEK 
Laboratory Manager Laboratory Services 
Manager.  
Responsible for 
ensuring 
appropriate 
resources are 
allocated (V). 
Medium (V) Will ensure 
capacity for 
increasing 
workload 
without 
increasing 
staff. 
Medium (V) 
Capital 
expenditure 
so will 
impact 
budget 
Medium (V) 
Will report directly to 
hospital manager to 
ensure allocation of 
capital investment. 
Medium (V) 
Very willing to 
allocate 
laboratory 
resources but 
must adhere to 
hospital politics. 
Medium (V) 
High power and 
influence within the 
department but low 
power and influence 
within hospital. 
Appendix 4 Stakeholder Analysis 
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Hospital Manager  Responsible for 
approving the 
funding for the 
project (V). 
Medium (V) 
 
Return on 
investment. 
Ensure that 
increasing 
workloads are 
met by 
automation. 
Low (V) 
Greater 
competing 
issues.  
 
High (V)  
Responsible for 
approving the funding 
for the project. 
Low (V) 
 
High (V) 
Quality Officer Responsible for the 
Quality 
Management 
System in the 
department. 
Ensuring that the 
change process 
adheres to the 
quality 
management 
system within the 
laboratory and 
complies with 
ISO:15189 
Responsible for 
signing off on 
validation plan and 
final report. 
Authorisation of 
new standard 
operating 
procedures. 
High (E/V) Increase in 
workload. 
Medium 
(E/V) 
Increase in 
workload 
during 
planning 
and 
implementat
ion. But little 
impact once 
full 
implemente
d. 
High (E/V) 
Responsible for the 
Quality Management 
System in the 
department. 
Medium (E/V) 
Motivated as it is 
a quality 
improvement 
initiative but it 
will increase 
workload during 
implementation. 
Medium (E/V) 
Limited time as also 
implementing  Q-Pulse in 
the laboratory.   
 
Senior Medical 
Scientists 
Responsible for the 
day-to-day 
management of 
microbiology lab.  
Allocation of time 
for the change 
(V/E). 
Validation (V/E) 
Implementation of 
guidelines (V/E). 
High (V/E) Increase in 
workload. 
Personal 
impact. 
Understanding
. 
High (V/E) 
Increased 
workload 
during 
valiation. 
High (V/E) 
Increased 
workload 
during 
valiation. 
Medium (V/E) 
Create costing analysis. 
Medium (V/E) 
Willing to make 
the change but 
fear of unknown. 
High 
commitment to 
quality. 
Low (V/E) 
New skill set required. 
Little working knowledge 
about new guidelines 
and technology. 
Absence of learning 
culture in the 
department. 
 
Medical Scientists Routine scientific 
work. 
Validation (V/E) 
Implementation of 
guidelines (V/E). 
High (V/E) Low (V/E) 
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Infection Prevention 
and Control Nurse 
IPC in the 
organisation 
None Low (V/E) 
Interest in 
decrease TAT 
for MRSA.  
Too busy. 
Understanding 
Low (V/E) 
However 
must keep 
informed as 
may detect 
MDRO 
which 
increase 
workload. 
Low (V/E) Low (V/E) Low (V/E) 
bioMerieux Manufacturer of 
VITEK 2 Compact 
Installation 
qualification of 
VITEK.  
Initial training 
Supplier of 
consumables 
High (V) 
 
To ensure 
customer 
satisfaction 
Medium (V) 
Required 
on-site 
during initial 
phase 
Medium (V) 
Provide technical 
support and servicing.  
High (V) 
This is their business- the routine service 
they provide.   
INAB National 
Accreditation Body 
Accreditation of 
microbiology 
services 
High (V/E) Ensure new 
processes 
meet 
standards 
outlined in 
ISO:15189 
Low (V/E) High (V/E) 
The must be informed of 
the new methodologies 
prior to inspection.  
High (V/E/) 
This is their business- the routine service 
they provide.   
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March 2015 Stakeholder Analysis 
Stakeholder Job Role Project Role Interest* Why?** Impact* Responsibility* Readiness* Capacity* 
Consultant 
Microbiologist 
Clinical lead for the 
department 
Clinical decision 
maker for the 
implementation of 
guidelines. 
Power and 
influence to ensure 
that appropriate 
resources are 
allocated to the 
project (E/V). 
High (E) Quality 
Improvement 
High 
May result 
in an 
increase of 
queries due 
to 
interpretive 
comments. 
Medium (E) 
Responsible for clinical 
input. 
High 
 
High 
 
Medium (V) Automation 
will enable 
introduction of 
MDRO 
guidelines and 
screening for 
HCAI 
Low (V) Low (V) 
 
High (E) 
Very excited 
about the 
prospect of 
automation.  
Competitive 
advantage over 
other labs in the 
group. 
High 
Laboratory Manager Laboratory Services 
Manager.  
 Medium  Will ensure 
capacity for 
increasing 
workload 
without 
increasing 
staff. 
Low 
 
Low 
 
Medium (V) 
Competitive 
advantage over 
other labs in the 
group. 
Medium (V) 
High power and 
influence within the 
department but low 
power and influence 
within hospital. 
Hospital Manager   Low 
 
Return on 
investment. 
Ensure that 
increasing 
workloads are 
met by 
automation. 
Low (V) 
Greater 
competing 
issues.  
 
Low Low (V) 
 
High (V) 
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Quality Officer Responsible for the 
Quality 
Management 
System in the 
department. 
Point of contact for 
INAB audit.  
High (E/V) Increase in 
workload. 
Medium 
(E/V) 
 
High (E/V) 
Responsible for the 
Quality Management 
System in the 
department. 
Medium (E/V) 
Motivated as it is 
a quality 
improvement 
initiative but it 
will increase 
workload during 
implementation. 
Medium (E/V) 
Limited time as also 
implementing  Q-Pulse in 
the laboratory.   
 
Senior Medical 
Scientists 
Responsible for the 
day-to-day 
management of 
microbiology lab.  
Mainstreaming High (V/E) Increase in 
workload. 
Personal 
impact. 
. 
High (V/E) 
Increased 
workload 
during 
valiation. 
. 
Medium (V/E) 
Sign off on training 
records.  
High (V/E) High (V/E) 
 
Medical Scientists Routine scientific 
work. 
Mainstreaming High (V/E) Low (V/E) 
Infection Prevention 
and Control Nurse 
IPC in the 
organisation 
None Low (V/E) 
Interest in 
decrease TAT 
for MRSA.  
Too busy. 
Understanding 
Low (V/E) 
However 
must keep 
informed as 
may detect 
MDRO 
which 
increase 
workload. 
Low (V/E) Low (V/E) Low (V/E) 
bioMerieux Manufacturer of 
VITEK 2 Compact 
Supplier of 
consumables 
Low (V) 
 
To ensure 
customer 
satisfaction 
Medium (V) Medium (V) 
Provide technical 
support and servicing.  
High (V) 
This is their business- the routine service 
they provide.   
INAB National 
Accreditation Body 
Accreditation of 
microbiology 
services 
High (V/E) Ensure new 
processes 
meet 
standards 
outlined in 
ISO:15189 
Low (V/E) High (V/E) 
The must be informed of 
the new methodologies 
prior to inspection.  
High (V/E/) 
This is their business- the routine service 
they provide.   
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Appendix 4 Risk Assessment 
 
Process
Severity
(1-5)
Likelihood
(1-5)
Risk 
Factor
Risk 
Rating
Q-Pulse 
Action No.
5 5 25 High
BST/QA/VP/032
5 3 15 High
BST/QA/VP/032
5 2 10 Medium
BST/QA/VP/032
2 2 4 Low
4 2 8 Medium
BST/QA/VP/032
5 5 25 High
BST/QA/VP/032
5 2 10 Medium
BST/QA/VP/032
3 5 15 High
BST/QA/VP/032
3 4 12 Medium
BST/QA/VP/032
BON SECOURS HOSPITAL TRALEE PATHOLOGY DEPARTMENT
Authorised By
Linda O'Reilly
Number Version Date of Issue
BST/PATH/F/028 1 04/01/2015
Title: Process Risk Assesssment Form
EUCAST guidelines are updated 
annually. VITEK2 software is not. 
Staff may not have the 
required time to participate 
INAB may not be satisfied 
with the validation of the 
The incorrect guidelines 
may be applied by the 
For the initial training the LM will 
ensure additional staff. This will be 
The opperational qualification of the 
VITEK 2 Compact will ensure that 
Staff are not familiar with 
EUCAST AST guidelines
The most current version of 
EUCAST guidelines may 
A contingency plan will be developed 
as part of the implementation plan. 
Staff do not have the 
training required to perform 
A contingency plan will be developed 
as part of the implementation plan. 
The new processes will be validated 
according to ISO:15189 standards, the 
Training may not be 
delivered by bioMerieux on 
Staff Training
Training will be provided for all staff 
on the use of the VITEK 2 Compact. 
Evaluate each risk identified.  Refer to BST/PATH/SOP/013 for guidance
Additional Control(s) RequiredExisting Control (s)Risk Identified
Introduction of the VITEK2 and EUCAST Guidelines
List the individual sub-processes (steps within the process), including any support processes.  Outline risks associated with each process documented
Identification and AST of bacteria using the VITEK 2 Compact
Name of Sub-Process
Staff do not have the training required to perform process
Identification and AST of bacteria using the VITEK 2 Compact
Identification and AST of bacteria using the VITEK 2 Compact
Risk Identified
Interpretation of antibiotic MIC values with EUCAST guidelines
Identification and AST of bacteria using the VITEK 2 Compact Training may not be delivered by bioMerieux on the agreed dates
There is no back up instrument if there is instrument downtime
Identification and AST of bacteria using the VITEK 2 Compact INAB may not be satisfied with the validation of the instrument
Staff are not familiar with EUCAST AST guidelines
Interpretation of antibiotic MIC values with EUCAST guidelines The incorrect guidelines may be applied by the VITEK 2
Interpretation of antibiotic MIC values with EUCAST guidelines
Cara Wrenn and Mary B. Murphy
Department Microbiology
Completed By
The most current version of EUCAST guidelines may not be on the VITEK 2 software.
Training will be provided for all staff 
on the use of the EUCAST guidelines. 
There may be a problem 
with the delivery of 
There is no back up 
instrument if there is 
There may be a problem with the delivery of reagents
Staff may not have the required time to participate in training
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Appendix 5 Gantt Chart 
Project Steps Sep. Oct. Nov. Dec. Jan. Feb. Mar. Apr. May 
Initiation: Meet laboratory manager to discuss project.          
Initiation: Literature Review          
Initiation: Project Management Tools: SWOT, Force-field 
and Stakeholder analysis 
         
Initiation: Create project proposal          
Planning: Develop preliminary project plan          
Planning: Meet stakeholders and discuss their concerns 
and requirements for plan  
         
Implementation: Training           
Implementation: Write new AST and identification SOPs          
Mainstreaming: Staff meetings; status updates and 
successes of project 
         
Evaluation: IQ, OQ           
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Project Steps Sep. Oct. Nov. Dec. Jan. Feb. Mar. Apr. May 
Evaluation: PQ          
Evaluation: Consumable costs          
Evaluation: Training          
Write up study          
Poster Presentation          
Submit Thesis         13th 
May 
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Appendix 6: Hardens 10 Questions to ask when planning a course 
or curriculum  
 
1. What are the needs in relation to the product of the training 
programme? 
All SMS/MS: 
a) Must understand the clinical application of the VITEK 2 Compact 
software.  
b) Have a working knowledge of EUCAST guidelines and an 
understanding of how the guidelines should be applied in clinical 
practise.  
c) Be able to use the VITEK 2 Compact for the routine identification 
and AST of bacteria. 
d) Know and understand the limitations of both the VITEK 2 
Compact and EUCAST guidelines.  
CM: 
a) Must understand the clinical application of the VITEK 2 Compact 
software.  
b) Have a working knowledge of EUCAST guidelines and an 
understanding of how the guidelines should be applied in clinical 
practise.  
c) Know and understand the limitations of both the VITEK 2 
Compact and EUCAST guidelines.  
 
2. What are the Aims and Objectives of the Programme? 
All staff will be trained to use the VITEK 2 Compact and EUCAST 
guidelines. Staff will score 100% in post training competency tests 
and will be fully compliant with the new procedures by 10/4/2015. 
 
3. What content should be included? 
The positive vision for change should be articulated to begin each 
training session (Schein, 1999 p115). There should be two formal 
presentations, one on the VITEK2 Compact and the other on 
EUCAST guidelines (Schein, 1999 p115). The content for the 
VITEK2 Compact will be supplied and presented by the bioMerieux 
116 
 
Application Specialist. The content for the EUCAST presentation is 
prescribed by EUCAST and available at www.eucast.org.  
Hand-on practical training for both VITEK2 Compact and EUCAST 
guidelines will also be provided. 
4. How should the content be organised? 
As the bioMerieux AS are delivering the VITEK2 Compact 
presentation and the initial hands-on practical training, EUCAST and 
VITEK2 impact training will be given separately.  
5. What educational strategies should be adopted? 
Harden describes 6 different education strategies. The approach 
used for this project will be a systematic approach- learning 
experiences are planned and recorded. This is important from an 
accreditation and QMS perspective.  
6. What teaching methods should be used? 
a) Student Grouping: For the initial stages all staff members will 
be trained together. However as the project progresses, 
group and individual hands-on training will be provided 
(Schein, 1999 p116).  
b) Delivery of Material: For the initial stages a power-point 
presentation will be used to deliver the background, routine 
use, clinical application and key information points for both 
VITEK2 Compact and EUCAST guidelines. Subsequent 
training will be practical experience through observation, 
followed by ‘doing’ and then supervision by the trainer. This 
will be based on the standard operating procedure.  
 
7. How should assessment be carried out? 
Assessment will be carried out as per the requirements of the 
Pathology Training SOP.  
a) Competency Assessment based on  
i. direct observation by the trainer (witness audit). This 
ensures compliance with the SOP and the guidelines. 
ii. written assessment (short answer questions) on the 
procedure and guidelines.  
b) Proficiency Testing using EQA samples 
 
8. How should the details of the curriculum be communicated? 
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Details of the training plan will be discussed at a microbiology 
meeting, where the implementation plan will be discussed in detail. 
9. What educational environment or climate should be fostered? 
A supportive and facilitative environment where trainees feel safe 
will be very important. The learners will be asked to provide 
feedback and the support of the trainer will be on-going beyond the 
life-span of this project (Schein, 1999 p115-116).  
10. How should the process be managed? 
In light of past experience with both VITEK2 Compact and EUCAST 
guidelines the change agent will be the primary trainer. However all 
departmental training will be supervised by the SMS responsible for 
training and approved by the QM.  
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Appendix 7: Gap Analysis CLSI and EUCAST Guidelines 
Document circulated at meeting with Senior Medical Scientist and 
Consultant Microbiologist 
Problem Suggested Solution if 
applicable. 
Comments: 
First reading point on 
the VITEK is higher 
than the EUCAST 
breakpoint, therefore 
susceptible isolates 
must be confirmed. 
Mupirocin disc on all 
MRSA isolates 
 
Agreed Solution 
Chloramphenicol is not 
on the ST01 VITEK 
Card.  
 
Put up manually when 
topical sensitivities are 
required i.e. eye swabs 
Agreed Solution 
Inducible Clindamycin 
Resistance (ICR): 
Screened for on VITEK.  
EUCAST suggest an 
interpretative comment 
is added to report? 
Edit erythromycin and 
clindamycin results 
based on ICR result. Set 
up a rule on VITEK for 
this. 
Agreed Solution  
Leave 
interpretative 
comment off 
report. Release 
edited result, ICR 
interpretative 
comments are 
unnecessary. 
Nitrofurantoin: 
Guidelines are only for 
Enterococci, Group B 
Strep and E. coli. 
Only report 
Nitrofurantoin on these 
organisms. Set up a rule 
on VITEK for this. Offer 
clinical advice if it is 
requested from on other 
organisms. 
Agreed Solution 
Metronidazole testing 
for anaerobes; there are 
no disc diffusion 
guidelines.  
Put up E-test on all 
clinically significant 
anaerobes and record 
MTZ susceptibility as an 
identification test only. 
Agreed Solution 
MTZ e-test on all 
isolates from 
blood culture and 
normally sterile 
sites.  
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Trimethoprim/ 
Staphylococci: 
guidelines for 
uncomplicated UTI only. 
 
Only report trimethoprim 
on Staphylococci from 
UTI. Offer clinical advice 
if requested for other 
infections. Set up a rule 
on VITEK for this. 
Agreed Solution 
Can omit 
interpretative 
comment as 
antibiotics will only 
be released as 
appropriate. 
Can no longer use the 
same concentration of 
ampicillin for 
Enterococci and 
Enterobacteriaceae. 
Validate both 
concentrations of 
ampicillin, Amp2 for 
Enterococci and Amp10 
for Enterobacteriaeceae 
(Contingency discs). 
Agreed Solution 
 
Cipro should only be 
reported for 
uncomplicated UTI’s. 
Nitro/Trimethoprim is for 
uncomplicated UTI’s 
only 
Set up a rule on VITEK 
for uncomplicated UTI 
isolates.  
Agreed Solution 
Can omit 
interpretative 
comment as 
antibiotics will only 
be released as 
appropriate. 
Group B Strep in Urine: 
Use penicillin to infer 
ampicillin and 
augmentin. 
No longer need to test 
for ampicillin and 
augmentin separately.  
Agreed Solution 
Haemophilus sp: 
Erythromycin is used to 
deduce clarithromycin 
sensitivity. 
Release both on the 
reports to guide clinician  
Agreed Solution 
Penicillin Susceptibility 
For S. pneumoniae: 
There are 3 different 
category interpretations: 
Meningitis, Pneumonia 
and Other infections. 
Add interpretive dosing 
comments to each one 
and release OR set up 
an apex rule to only 
release the required 
category depending on 
site of infection and 
clinical details.  
Option 2: set up 
an apex rule to 
only release the 
required category 
depending on site 
of infection and 
clinical details. 
Penicillin 
(Meningitis)               
Penicillin 
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(Pneumonia) 
Penicillin 
(infections other 
than meningitis 
and pneumonia 
 
EUCAST do not 
recommend editing 
beta-lactam results 
when an ESBL or 
AmpC producer is 
identified.  
Edit results on detection 
of these MDRO OR 
Implement strict 
EUCAST guidelines.  
For infection 
control protocols 
and also due to 
literature, results 
will be edited. A 
rule will be set up 
on the VITEK to 
ensure that these 
isolates are 
flagged to the 
user.  
Add a comment to 
the report 
prompting 
infection control 
protocols and 
MDRO.  
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Appendix 8 Poster 
 
